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COMPOUNDS AND METHOD OF USE AS 
ANTI-INFECTION COMPOUNDS AND 
THERAPEUTIC AGENTS TO REGULATE 
CHOLESTEROL METABOLISM 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application claims the benefit of U.S. Provisional 
Patent Application No. 61/814,067, filed Apr. 19, 2013, 
herein incorporated by reference. 
FIELD OF THE INVENTION 
2 
protein in S. cerevisiae. A few years later, Soltis, et al. (4) 
isolated a similar allele of the human squalene synthase gene 
by screening a human cDNA library with a rat squalene 
synthase gene probe. These investigators also determined 
that the human squalene synthase gene was not able to 
complement an erg9 deficiency in yeast. They were, how­
ever, able to document expression of the human squalene 
synthase gene in yeast by recording the corresponding 
protein by immuno-blotting methodology, as well as mea-
lO 
suring inducible enhancement of SS enzyme activity. This 
result conflicted with the notion that a heterologously 
expressed SS was not able to complement the erg9 defi­
ciency in yeast because of problems with transgene expres-
15 sion or protein stability in yeast, and Soltis, et al. (4)
hypothesized that structural differences in the carboxy­
termini of the yeast and human SS may affect localization or 
folding of the proteins in association with intracellular 
membranes. 
The presently disclosed subject matter relates to novel 
compounds and methods and systems for unique infection 
control reagents and new therapeutics. In one example, the 
presently disclosed subject matter related to novel com­
pounds and methods and systems for unique ergosterol 
control reagents, new therapeutics to regulate stern! metabo- 20 
!ism in humans and plants, and herbicide compositions. The
novel compounds include a functional domain from
squalene synthases, e.g. from S. cerevisiae, such as a 26
amino acid linker-domain. Alternatively, the compounds can
include a portion that mimic the 26 amino acid linker­
domain. These compounds can be formulated into anti­
fungal compounds. The present invention also relates to
therapeutic agents for controlling cholesterol metabolism
and ergosterol metabolism in non-fungal organisms based
The first plant SS was cloned from Arabidopsis (5) and 
soon after from Nicotiana benthamiana (6). Nakashima, et 
al. (5) failed to isolate anArabidopsis SS gene by screening 
for complementation of an erg9 deficient yeast line, and 
instead screened plaques of an Arabidopsis cDNA library 
25 with a mouse squalene synthase cDNA probe. Hanley, et al. 
( 6) used a degenerate primer/PCR approach to isolate a N.
benthamiana SS, and likewise noted that the tobacco SS 
gene was unable to restore growth when expressed in an 
erg9 deficient yeast strain. Later, Kribii et al. (7) reported
on the aforementioned and other novel compounds which
include a peptide sequence from a linker domain of squalene
synthase (e.g. the 26 amino acid) linker-domain from S.
cerevisiae or sequences which mimics the domain. Some of
the therapeutic agents may be herbicides.
BACKGROUND OF THE INVENTION 
The first squalene synthase (SS) gene to be functionally 
characterized was isolated from Saccharomyces cerevisiae 
and cloned concurrently by the Karst and Robinson groups 
(1,2). Both groups utilized the strategy of screening S. 
cerevisiae genomic library clones for their ability to func­
tionally complement a squalene synthase (erg9)-deficient 
yeast line. Interestingly, Jennings, et al. (2) found that a 
genomic clone containing only a partial SS gene fragment 
was able to restore ergosterol prototrophy even though it 
only restored 5% of the normal level of SS enzyme activity. 
This finding suggested that low levels of SS enzyme activity 
were sufficient to complement the erg9 deficiency in yeast. 
Soon afterwards, Robinson, et al. (3) attempted to clone the 
SS gene from Homo sapiens and S. pombe using the same 
strategy, but isolated only the S. pombe gene by screening 
for complementation of the er9-deficient line (3). Having 
two SS genes from two species of fungi, these investigators 
were able to identify conserved regions within the deduced 
protein sequences to which they designed degenerate prim­
ers and cloned the human SS homolog using PCR (3). 
Robinson, et al. (3) confirmed that the human squalene 
synthase gene was unable to restore ergosterol prototrophy 
to the erg9-deficient yeast line, but a chimera SS gene 
constructed by combining a 5' region of the human gene 
containing the putative catalytic domain with a 3' region of 
the S. cerevisiae gene containing a membrane-anchoring 
domain was able to complement the erg9 deficiency. Rob­
inson, et al. (3) suggested that the inability of human SS to 
functionally complement the erg9-deficient yeast line was 
due to problems with expression or stability of the human 
30 that the Arabidopsis genome contained two highly homolo­
gous SS genes organized in a tandem array. This group 
confirmed that the Arabidopsis SS could not complement the 
erg9 (SS gene) disruption in yeast, but they measured 
significant SS enzyme activity in the microsomal fraction of 
35 these yeast. These investigators went on to show that a 
chimeric Arabidopsis SS gene containing a substitution 
corresponding to the 66 carboxy-terminal amino acids of 
Arabidopsis SS with 111 carboxy-terminal amino acids of 
the S. pombe SS were sufficient to restore prototrophic 
40 growth of the erg9 knockout in yeast without exogenous 
stern!. Radiolabeling studies were also performed with [3H]­
FPP fed to microsomes isolated from yeast expressing either 
the full length Arabidopsis SS or the Arabidopsis-S. pombe 
chimera SS genes, or from wild type yeast. Radiolabel was 
45 incorporated by either the wild type yeast microsomes or 
microsomes from the erg9-deficient yeast over-expressing 
the Arabidopsis-S. pombe chimera SS into squalene, 
squalene-2,3-epoxide, and lanosterol. However, when [3H]­
FPP was incubated with microsomes from erg9 deficient 
50 yeast expressing the full length Arabi do psis SS, only radio­
labeled squalene was detected. No SS enzyme activity was 
detectable in the cytosolic (soluble) fractions of these yeast 
lines. These results strongly suggested that active SS was 
being expressed and targeted to membrane in all the con-
55 structs tested; however, the carboxy-terminal 111 amino 
acids of S. pombe were necessary for channeling of squalene 
into the ergosterol biosynthetic pathway (7). 
In 2000, another fungal squalene synthase was isolated 
from Yarrowia li polytica using a degenerate primer 
60 approach (8). The Y. lipolytica SS was found to complement 
an erg9 deficient yeast line, albeit the complemented yeast 
grew slower than the yeast complemented with the S. 
cerevisiae SS gene. Altogether, this result and those of the 
other investigators demonstrated that at least three different 
65 fungal SS could complement the erg9 knockout in S. cer­
evisiae, but no other SS isolated from animal or plant could 
accomplish this task. 
US 9,821,037 Bl 
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In 2008, Busquets, et al. (9) reported that of the two 
annotated SS genomic sequences in Arabidopsis, only one 
coded for a functional SS enzyme. Busquets, et al. also 
performed some fluorescence microscopy experiments to 
determine the intracellular location of Arabidopsis SS (9). 5 
GFP was tagged to the N-terminus of a full length SS, a SS 
lacking the equivalent of the carboxy-terminal 67 amino 
acids, or the GFP was fused directly to a gene fragment 
corresponding to that encoding for the carboxy-terminal 67 
amino acids of the SS. All three constructs were transiently 10 
co-expressed in onion epidermal cells with an ER-targeted 
version of DsRed. Both the GFP linked to the full length SS 
and the carboxy-terminal 67 amino acids of SS co-localized 
with DsRed, which indicated that these two SS enzymes 
were localized to the ER membrane. The GFP-SS fusion 15 
lacking the carboxy-terminal 67 amino acids appeared local­
ized to only the cytosol. These authors concluded that the 
membrane-sparming region at the carboxy-terminus of SS 
was critical for correct targeting of SS to the ER membrane 
4 
created by reciprocal swapping of the DNA sequences 
coding for the 91 carboxy-terminal amino acids ofYSS with 
the corresponding DNA segments of the algal (BSS, Botryo-
coccus squalene synthase) and plant (ASS and TSS, Arabi­
dopsis and tobacco squalene synthase) genes. An additional 
24 amino acid truncation of the YSS carboxy domain is 
indicated by a lack of color in the linear enzyme model. Each 
construct is annotated with the specific amino acids labeled 
above each depiction. Constructs were independently trans­
formed into a yeast erg9 knockout line, and three indepen­
dent transformants for each construct were randomly 
selected for growth in Yeast Synthetic Drop-out media 
containing 5 mg/I ergosterol. After three days, each culture 
was serially diluted with water to OD600=1, 0.2, 0.04, and 
0.008, and 5 µI of each dilution spotted on Yeast Synthetic 
Drop-out media plates lacking ergosterol. Plates were incu-
bated at 28° C. for 72 h. Liquid cultures of each transformant 
in TN-7 line were grown in 10 mL of Yeast Synthetic 
Drop-out media containing 5 mg/L ergosterol at room tem-
(9). 
These results and the present inventors' observations that 
the algal Botryococcus braunii SS also could not comple­
ment the erg9 mutant in yeast suggested that it was not 
simply targeting of squalene synthase enzyme activity to the 
ER membrane of yeast that was important. Some additional 
protein domain within the carboxy-terminal region of the 
yeast squalene synthase was necessary to facilitate the 
complementation phenotype. 
20 perature for seven days. Organic extracts were prepared and 
analyzed by GC-MS for their squalene content. To validate 
each gene construct, the squalene synthase enzyme activity 
encoded by each gene was assessed when the gene was 
expressed in Cali-7 yeast. Briefly, 2000xg supematants were 
25 prepared and used in enzyme assays containing 3H-FPP and 
radiolabeled products separated by TLC and analyzed. 
Enzyme activity (pmoles/h/µg total protein) is recorded as a 
percent of squalene synthase activity measured when the 
BRIEF DESCRIPTION OF THE DRAWINGS 30 
YSS gene was expressed in the yeast line. (n=3). 
FIG. 3 shows the amino acid alignment of the B. braunii 
(AF205791), C. reinhardtii (XM_001703395), A. thaliana 
(NM_119630), N. benthamiana (U46000.1), H. sapien 
(NM_004462), and R. norvegicus (NM_019238) squalene 
synthases relative to those for S. cerevisiae (X59959), S. 
FIG. 1 illustrates various full length and carboxy-termi­
nally truncated squalene synthase genes expressed in yeast 
line CALI7-1 to test for their ability to complement an erg9 
deletion. Terminal truncations are indicated by a lack of gray 
shading in the linear boxed enzyme model with the specific 
amino acid coordinates labeled above each. The squalene 
synthases tested are those of S. cerevisiae (YSS), B. braunii 
(BSS), R. norvegicus (RSS), N. benthamiana (TSS), and A. 
thaliana (ASS). For the erg9 complementation tests, three 
independent CALI7-1 transformants of each construct were 
randomly selected and grown in 2 mL Yeast Synthetic 
Drop-out media (Sigma) containing 5 mg/L ergosterol at 28° 
35 pombe (NM_001021271), and Y. lipolytica (AF092497) 
(Bottom Portion, B) as SEQ ID NOS: 13-24. The alignment 
is limited to the sequences corresponding to the 67 amino 
acid domain of the S. cerevisiae squalene synthase that are 
necessary and sufficient to restore ergosterol prototrophy to 
40 erg9 deficient yeast. The region boxed and identified as the 
truncated/conserved/linker-domain region corresponds to a 
stretch of 26 amino acids (SEQ ID NOS.: 1-12, respectively) 
that appear more conserved than other regions, and particu­
larly well conserved amongst the fungal squalene synthase's C. for three days, after which the culture was serially diluted 
with water to optical densities (600 nm) equal to 1, 0.2, 0.04, 
and 0.008, and 5 µL of each dilution spotted onto Yeast 
Synthetic Drop-out media plates without any exogenous 
ergosterol. Plates were incubated at 28° C. for 72 hours. 
Liquid cultures of each construct were also transformed into 
TN-7 (CALI7-1 containing an additional mutation to knock- 50 
out the squalene epoxidase gene, hence the genotype of 
TN-7 is erg9, ergl) were grown in 10 mL ofYeast Synthetic 
Drop-out media containing 5 mg/L ergosterol at room tem­
perature for seven days. Organic extracts were prepared and 
analyzed by GC-MS for their squalene content. To validate 55 
each gene construct, the squalene synthase enzyme activity 
encoded by each gene was assessed when the gene was 
expressed in Cali7-1 yeast. Briefly, 2,000xg supematants 
were prepared and used in enzyme assays containing 
3H-FPP and radiolabeled products separated by TLC and 60 
analyzed. Enzyme activity (pmoles/h/µg total protein) is 
recorded as a percent of squalene synthase activity measured 
when the YSS gene was expressed in the yeast line. (n=3). 
45 (Top portion, A) of SEQ ID NOS: 13-24, respectively. 
FIG. 2 shows the carboxy-terminal amino acids of YSS 
are necessary and sufficient when appended to heterologous 65 
squalene synthase genes to confer ergosterol prototrophic 
growth to an erg9 knockout yeast line. Constructs were 
FIG. 4 shows functional assessment of the role a 26 amino 
acid peptide sequence within fungal squalene synthases 
plays in facilitating the complementation of the erg9 mutant. 
Reciprocal constructs were created by swapping the indi­
cated 26 amino acids of the yeast squalene synthase (YSS) 
for the corresponding amino acids of an algal squalene 
synthase (BSS) and a higher plant squalene synthase (ASS). 
Three independent Cali-7 transformants for each construct 
were randomly selected, grown in Yeast Synthetic Drop-out 
media (Sigma) containing 5 mg/I ergosterol for three days, 
after which serial dilutions were prepared corresponding to 
optical densities at 600 nm equivalent to 1, 0.2, 0.04, and 
0.008, and 5 µI of each dilution spotted onto Yeast Synthetic 
Drop-out media plates lacking ergosterol. Plates were incu­
bated at 28° C. for 72 h. Liquid cultures of each transformant 
in TN-7 line were grown in 10 mL of Yeast Synthetic 
Drop-out media containing 5 mg/L ergosterol at room tem­
perature for seven days. Organic extracts were prepared and 
analyzed by GC-MS for their squalene content. To validate 
each gene construct, the squalene synthase enzyme activity 
encoded by each gene was assessed when the gene was 
expressed Cali-7 yeast. Briefly, 2000xg supematants were 
US 9,821,037 Bl 
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prepared and used in enzyme assays containing 3H-FPP and 
radiolabeled products separated by TLC and analyzed. 
Enzyme activity (pmoles/h/µg total protein) is recorded as a 
percent of squalene synthase activity measured when the 
YSS gene was expressed in the yeast line. n=3 
FIG. 5 shows evaluating the contribution of a carboxy­
terminal sequence of 26 amino acids conserved amongst 
fungi to the complementation and restoration of ergosterol 
prototrophy to an erg9 knockout yeast line. Full-length S. 
cerevisiae and Arabidopsis squalene synthase genes were 
10 
constructed in which the indicated amino acids correspond­
ing to residues 353 to 378 ofYSS and residues 345 to 370 
of ASS were exchanged with one another in either the YSS 
gene (mutants a-e) or the ASS gene (mutants f-j) (in lighter 15
gray, ASS amino acids substituted into the YSS gene; in 
darker gray, YSS residues substituted into the ASS gene). 
Each construct was independently transformed into the 
Cali7-1 erg9 mutant line, 3 independent transformants were 
randomly selected and grown in Yeast Synthetic Drop-out 20 
media (Sigma) containing 5 mg/I ergosterol for 3 days. 
Aliquots of each culture were then diluted with water to 
optical densities (600 nm) corresponding to 1, 0.2, 0.04, and 
0.008, and 5 µI of each dilution spotted on Yeast Synthetic 
Drop-out media plates lacking ergosterol. Plates were incu- 25 
bated at 28° C. for 72 h. Liquid cultures of each transformant
in TN-7 line were grown in 10 mL of Yeast Synthetic 
Drop-out media containing 5 mg/L ergosterol at room tem­
perature for seven days. Organic extracts were prepared and 
analyzed by GC-MS for their squalene content. To validate 30 
each gene construct, the squalene synthase enzyme activity 
encoded by each gene was assessed when the gene was 
expressed Cali-7 yeast. Briefly, 2000xg supematants were 
prepared and used in enzyme assays containing 3H-FPP and 
radiolabeled products separated by TLC and analyzed. 35 
Enzyme activity (pmoles/h/µg total protein) is recorded as a 
percent of squalene synthase activity measured when the 
YSS gene was expressed in the yeast line. n=3. 
FIG. 6 shows confocal microscopy images ofCali-7 yeast 
expressing various fluorescent tagged squalene synthase 40 
enzymes. Constructs were created by fusing efGFP or 
DsRedl in frame and connected by a (GSGG)2 linker to the 
amino terminus ofYSS, BSS-YSS-BSS (BYB), and YSStr, 
or BSS, respectively. These constructs were cloned into 
standard yeast expression vectors, Yep352-Ura or pESC- 45 
Leu. Various combinations of fluorescent-tagged squalene 
synthases or a CFP-tagged ER marker (12) were trans­
formed into Cali-7 yeast and positive transformants were 
grown in Yeast-synthetic Drop-out media containing 5 mg/L 
ergosterol for three days. Confocal laser scanning micro- 50 
graphs were acquired on an Olympus FVl 000 microscope 
(Olympus America Inc., Melville, N.Y.). 
6 
FIG. 8 shows a phylogenetic tree for the amino acid 
sequence aligriment of the 26 amino acid linker domain of 
squalene synthases from diverse organisms. The clustering 
of the sequences for plants (Plantae), animals (Animalia) 
and fungi (Fungi) are indicative of the uniqueness of these 
domains to the respective organisms in each kingdom and 
the distinct functional significance of this domain for each 
kingdom as illustrated in FIGS. 4 and 7 above. 
SUMMARY OF THE INVENTION 
The present invention relates to a compound consisting 
essentially of at least a portion of an amino acid linker­
domain for squalene synthase, e.g. squalene synthase from 
S. cerevisiae. In one specific form, the compound includes a
26 amino acid linker-domain, e.g. an amino acid domain
having a sequence of SEQ ID NO: 1. Alternatively, the
linker domain can have a different sequence from other
species having similar, conserved regions, including
sequences of SEQ ID NOS: 2-12.
The present invention, in another form, relates to the use 
of novel compounds which include or mimic the functional 
amino acid linker-domain from squalene synthase (SEQ ID 
NO: 1) including but not limited to an amino acid sequence 
of SEQ ID NOS: 1-12 as a new class of compounds, such as 
anti-infection agents, herbicides, etc., as provided by this 
disclosure. 
In addition, in one form or embodiment, the present 
invention relates to new therapeutic agents and methods for 
controlling cholesterol metabolism in humans using the 
aforementioned compounds. 
In yet an additional embodiment the present invention, a 
method is provided for treating or controlling stern! biosyn­
thesis by administering or applying a compound comprising 
at least a portion of an amino acid linker-domain from 
squalene synthase or a compound which mimics the physical 
and chemical properties of this compound, to a subject, in 
need of treatment, therefrom. 
The present invention is based on prior studies in which 
squalene synthase (erg9) deficient S. cerevisiae can be 
complemented by the squalene synthase genes of various 
fungi, but not those of plants or animals. However, the 
specific mechanism behind this phenomenon has remained 
enigmatic. The present invention is further based on iden-
tifying a stretch of26 amino acids which is highly conserved 
among fungal squalene synthases that does not affect cata­
lytic activity of the enzyme yet is necessary and sufficient to 
allow squalene synthase genes from any kingdom to 
complement erg9 mutants of S. cerevisiae. Within this 26 
amino acid domain, a stretch of four residues is almost 
completely conserved among fungi, and when changed, the 
yeast enzyme loses its ability to complement. These results 
FIG. 7 shows the 26 amino acid stretch ofYSS can inhibit 
the growth of yeast. Constructs were created in which the 
C-terminal 92 AA ofYSS, the C-terminal 64 AA ofYSS, the
C-terminal 66 AA of ASS, the C-terminal 92 AA ofYSS in
which the 26 AA domain is replaced by the corresponding of
ASS or BSS, and the C-terminus of either ASS or BSS in
which the 26 AA domain is replaced by the corresponding of
YSS were cloned into the pESC-Ura (Gall and GallO
promoters) vector. Constructs were transformed into
BY4741 yeast and positive transformants were grown in 2
mL of Yeast-Synthetic Drop-out medium for 4 days. Serial
dilutions (Corresponding to O.D.600=0.5, 0.1, 0.02, and 
0.004) were plated on selection media containing either
glucose or galactose as the carbon source. Pictures were
taken after 4 days growth at 28° C. 
55 provide evidence that this domain is required for squalene 
synthase to channel squalene into the stern! synthesis path­
way. Overexpression of the non-catalytic C-terminal resi­
dues of squalene synthase in S. cerevisiae prevents yeast 
growth, but only when the fungal 26 amino acid linker-
60 domain is included. This confirms the importance of this 
domain in substrate channeling and provides evidence that 
molecules that mimic this domain as a new class of anti­
fungal compounds, as well can be used new therapeutic 
agents for the control of cholesterol metabolism in humans. 
65 Further, due to the conservation of the amino acid linker­
domain in squalene synthase fungal species, the linker­
domain in the other fungal species can be used as a substitute 
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for that of the 26 amino acid linker-domain, m vanous 
embodiments of the present invention. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
Various embodiments of the present invention are based 
on the inventor's discovery that specific portions of a full 
length polypeptide/amino acid sequence for squalene syn­
thase can complement a erg9 mutation in yeast. In particular, 10 
it was discovered that an amino acid linker-domain from 
squalene synthase can complement the erg9 mutation, to 
restore squalene synthase activity. Based on this, compounds 
were created which comprise the amino acid linker-domain 
from squalene synthase. These compounds include peptides 15 
which have the sequences of the linker-domain from natu­
rally occurring organisms and can include those which 
mimic the function and structure of the linker-domain. 
8 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer­
ence to "a cell" includes a plurality of such cells, and so 
forth. 
Unless otherwise indicated, all numbers expressing quan­
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently­
disclosed subject matter. 
As used herein, the term "about," when referring to a In other embodiments, a method for treating or control­
ling cholesterol metabolism in humans includes administer­
ing a therapeutically effective amount of a compound com­
prising at least a portion of an amino acid linker-domain 
from squalene synthase, to a patient in need of treatment, 
therefrom. 
20 value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia­
tions of in some embodiments±20%, in some embodi­
ments±10%, in some embodiments±5%, in some embodi­
ments±!%, in some embodiments±0.5%, and in some 
In other embodiments, a method is provided for treating 
or controlling sterol biosynthesis by administering or apply­
ing a compound comprising at least a portion of an amino 
acid linker-domain from squalene synthase, to a subject, in 
need of treatment, therefrom. 
25 embodiments±0.1 % from the specified amount, as such 
variations are appropriate to perform the disclosed method. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
The present invention is based on specific examples and 30 
experiments conducted as will be described below. Based on 
those experiments and examples described below, the pres­
ent Inventors discovered novel compounds that either 
include an amino acid linker-domain of squalene synthase 
from S. cerevisiae or have domains or characteristics that 
mimic the amino acid linker-domain including but not 
limited to the 26 amino acid linker sequence of SEQ ID NO: 
two particular units are also disclosed. For example, if 10 
35 and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
1 as well as SEQ ID NOS: 2-12. For example, one of 
ordinary skill in the art based on the present disclosure will 
be able to identify other amino acid sequences which have 40 
the desired physical and chemical properties to that of 
compounds which include SEQ ID NO: 1. Further, the work 
reported here describes the inventors' efforts to use the erg9 
complementation test in yeast to map a specific peptide 
domain within the carboxy-terminal region of the yeast 45 
squalene synthase protein necessary for the complementa­
tion phenotype. 
Based on the experiments and results described below the 
aforementioned compounds can be used or formulated into 
anti-infection compounds such as antifungal compounds, 50 
anti-parasitic compounds and herbicides. Further, the afore­
mentioned compounds can be formulated as therapeutic 
agents to control cholesterol metabolism in humans. In 
addition, in accordance with the present disclosure, the 
aforementioned compounds can be used in various methods 55 
as antifungal compounds, anti-parasitic compounds and in 
therapeutic treatments to control cholesterol metabolism, 
ergosterol biosynthesis in fungi and other organisms depen­
dent on ergosterol for viability. 
While the terms used herein are believed to be well 60 
understood by one of ordinary skill in the art, definitions are 
set forth herein to facilitate explanation of the presently­
disclosed subject matter. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 65 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
In some embodiments of the presently-disclosed subject 
matter, pharmaceutical compositions comprise a portion of 
an amino acid linker domain from squalene synthase. The 
pharmaceutical composition may be included with a phar­
maceutically-acceptable vehicle, carrier, or excipient. In 
some embodiments, the pharmaceutical composition is phar­
maceutically-acceptable in humans. Also, as described fur­
ther below, in some embodiments, the pharmaceutical com­
position can be formulated as a therapeutic composition for 
delivery to a subject. 
A pharmaceutical composition as described herein pref­
erably comprises a composition that includes a pharmaceu­
tical carrier such as aqueous and non-aqueous sterile injec­
tion solutions that can contain antioxidants, buffers, 
bacteriostats, bactericidal antibiotics and solutes that render 
the formulation isotonic with the bodily fluids of the 
intended recipient; and aqueous and non-aqueous sterile 
suspensions, which can include suspending agents and 
thickening agents. The pharmaceutical compositions used 
can take such forms as suspensions, solutions or emulsions 
in oily or aqueous vehicles, and can contain formulatory 
agents such as suspending, stabilizing and/or dispersing 
agents. Additionally, the formulations can be presented in 
unit-dose or multi-dose containers, for example sealed 
ampoules and vials, and can be stored in a frozen or 
freeze-dried or room temperature (lyophilized) condition 
requiring only the addition of sterile liquid carrier immedi­
ately prior to use. 
In some embodiments, solid formulations of the compo­
sitions for oral administration can contain suitable carriers or 
excipients, such as corn starch, gelatin, lactose, acacia, 
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sucrose, microcrystalline cellulose, kaolin, mannitol, dical­
cium phosphate, calcium carbonate, sodium chloride, or 
alginic acid. Disintegrators that can be used include, but are 
not limited to, microcrystalline cellulose, com starch, 
sodium starch glycolate, and alginic acid. Tablet binders that 
can be used include acacia, methylcellulose, sodium car­
boxymethylcellulose, polyvinylpyrrolidone, hydroxypropyl 
methylcellulose, sucrose, starch, and ethylcellulose. Lubri­
cants that can be used include magnesium stearates, stearic 
acid, silicone fluid, talc, waxes, oils, and colloidal silica. 
10 
Further, the solid formulations can be uncoated or they can 
10 
The compositions can further be formulated as topical 
semi-sold ointment or cream formulations can contain a 
concentration of the presently-described compositions in a 
carrier such as a pharmaceutical cream base. Various for­
mulations for topical use include drops, tinctures, lotions, 
creams, solutions, and ointments containing the active ingre­
dient and various supports and vehicles. The optimal per­
centage of the therapeutic agent in each pharmaceutical 
formulation varies according to the formulation itself and 
the therapeutic effect desired in the specific pathologies and 
correlated therapeutic. In some embodiments, such ointment 
or cream formulations can be used for trans-dermal delivery 
of the pharmaceutical compositions described herein or for 
delivery to certain organs. 
Injectable formulations of the compositions can contain 
various carriers such as vegetable oils, dimethylacetamide, 
dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl 
myristate, ethanol, polyols (glycerol, propylene glycol, liq­
uid polyethylene glycol), and the like. For intravenous 
injections, water soluble versions of the compositions can be 
administered by the drip method, whereby a formulation 
including a pharmaceutical composition of the presently­
disclosed subject matter and a physiologically-acceptable 
excipient is infused. Physiologically-acceptable excipients 
can include, for example, 5% dextrose, 0.9% saline, Ring-
er's solution or other suitable excipients. Intramuscular 
preparations, e.g., a sterile formulation of a suitable soluble 
salt form of the compounds, can be dissolved and adminis-
be coated by known techniques to delay disintegration and 
absorption in the gastrointestinal tract and thereby provide a 
sustained/extended action over a longer period of time. For 
15 
example, glyceryl monostearate or glyceryl distearate can be 
employed to provide a sustained-/extended-release formu­
lation. Numerous techniques for formulating sustained 
release preparations are known to those of ordinary skill in 
the art and can be used in accordance with the present 20 
invention, including the techniques described in the follow­
ing references: U.S. Pat. Nos. 4,891,223; 6,004,582; 5,397, 
574; 5,419,917; 5,458,005; 5,458,887; 5,458,888; 5,472, 
708; 6,106,862; 6,103,263; 6,099,862; 6,099,859; 6,096, 
340; 6,077,541; 5,916,595; 5,837,379; 5,834,023; 5,885, 25 
616; 5,456,921; 5,603,956; 5,512,297; 5,399,362; 5,399, 
359; 5,399,358; 5,725,883; 5,773,025; 6,110,498; 5,952, 
004; 5,912,013; 5,897,876; 5,824,638; 5,464,633; 5,422, 
123; and 4,839,177; and WO 98/47491, each of which is 
incorporated herein by this reference. 
Liquid preparations for oral administration can take the 
form of, for example, solutions, syrups or suspensions, or 
they can be presented as a dry product for constitution with 
water or other suitable vehicle before use. Such liquid 
preparations can be prepared by conventional techniques 35 
with pharmaceutically-acceptable additives such as sus­
pending agents ( e.g., sorbitol syrup, cellulose derivatives or 
hydrogenated edible fats); emulsifying agents (e.g. lecithin 
30 tered in a pharmaceutical excipient such as Water-for-Injec­
tion, 0.9% saline, or 5% glucose solution. A suitable 
insoluble form of the composition can be prepared and 
administered as a suspension in an aqueous base or a 
pharmaceutically-acceptable oil base, such as an ester of a 
long chain fatty acid, ( e.g., ethyl oleate ). 
or acacia); non-aqueous vehicles (e.g., almond oil, oily 
esters, ethyl alcohol or fractionated vegetable oils); and 40 
preservatives ( e.g., methyl or propyl-p-hydroxybenzoates or 
sorbic acid). The preparations can also contain buffer salts, 
flavoring, coloring and sweetening agents as appropriate. 
Preparations for oral administration can be suitably formu­
lated to give controlled release of the active compound. For 45 
buccal administration, the compositions can take the form of 
capsules, tablets or lozenges formulated in conventional 
manner. 
In addition to the formulations described above, compo­
sitions comprising the amino acid linker domain of squalene 
synthase or compounds which mimic this domain of the 
presently-disclosed subject matter can also be formulated as 
rectal compositions, such as suppositories or retention 
enemas, e.g., containing conventional suppository bases 
such as cocoa butter or other glycerides. Further, the present 
compositions can also be formulated as a depot preparation 
by combining the compositions with suitable polymeric or 
hydrophobic materials (for example as an emulsion in an 
acceptable oil) or ion exchange resins, or as sparingly 
soluble derivatives, for example, as a sparingly soluble salt. 
For administration of a therapeutic composition as dis­
closed herein ( e.g., a composition comprising an amino acid Various liquid and powder formulations can also be 
prepared by conventional methods for inhalation into the 
lungs of the subject to be treated or for intranasal adminis­
tration into the nose and sinus cavities of a subject to be 
treated. For example, the compositions can be conveniently 
delivered in the form of an aerosol spray presentation from 
pressurized packs or a nebulizer, with the use of a suitable 
propellant, e.g., dichlorodifluoromethane, trichlorofluo­
romethane, dichlorotetrafluoroethane, carbon dioxide, or 
other suitable gas. Capsules and cartridges of, for example, 
gelatin for use in an inhaler or insufllator may be formulated 
containing a powder mix of the desired compound and a 
suitable powder base such as lactose or starch. 
The compositions can also be formulated as a preparation 
for implantation or injection. Thus, for example, the com­
positions can be formulated with suitable polymeric or 
hydrophobic materials ( e.g., as an emulsion in an acceptable 
oil) or ion exchange resins, or as sparingly soluble deriva­
tives (e.g., as a sparingly soluble salt). 
50 linker-domain from squalene synthase), conventional meth­
ods of extrapolating human dosage based on doses admin­
istered to a murine animal model can be carried out using the 
conversion factor for converting the mouse dosage to human 
dosage: Dose Human per kg=Dose Mouse per kgx12 
55 (Freireich, et al., (1966) Cancer Chemother Rep. 50: 219-
244). Doses can also be given in milligrams per square meter 
of body surface area because this method rather than body 
weight achieves a good correlation to certain metabolic and 
excretionary functions. Moreover, body surface area can be 
60 used as a common denominator for drug dosage in adults 
and children as well as in different animal species as 
described by Freireich, et al. (Freireich et al., (1966) Cancer 
Chemother Rep. 50:219-244). Briefly, to express a mg/kg 
dose in any given species as the equivalent mg/sq m dose, 
65 multiply the dose by the appropriate kg factor. In an adult 
human, 100 mg/kg is equivalent to 100 mg/kgx37 kg/sq 
m=3700 mg/m2. 
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Suitable methods for administering a therapeutic compo­
sition in accordance with the methods of the presently­
disclosed subject matter include, but are not limited to, 
systemic administration, parenteral administration (includ­
ing intravascular, intramuscular, and/or intraarterial admin­
istration), oral delivery, buccal delivery, rectal delivery, 
subcutaneous administration, intraperitoneal administration, 
inhalation, dermally (e.g., topical application), intratracheal 
installation, surgical implantation, transdermal delivery, 
local injection, intranasal delivery, and hyper-velocity injec- 10 
tion/bombardment. Where applicable, continuous infusion 
can enhance drug accumulation at a target site (see, e.g., 
U.S. Pat. No. 6,180,082). In some embodiments of the 
therapeutic methods described herein, the therapeutic com­
positions are administered orally, intravenously, or intrap- 15 










SEQ ID NO: 
160 
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Since Tc and Ld have similar squalene synthase linker­
domain sequences to the squalene synthase linker-domain 
sequence in S. cerevisiae (as well as other organisms iden­
tified in this disclosure, including FIG. 3, below), anti­
infection agents can be formulated from compounds having 
at least a portion of an amino acid linker-domain from 
squalene synthase. These formulated compounds can admin-
istered or applied to treat infections, which include fungal 
and parasitic infections. The squalene synthase can have an 
amino acid sequence of SEQ ID NOS: 1-12 and/or can have 
a different sequence that mimics the physical and chemical 
properties of SEQ ID NOS: 1-12. The treatment can com-
20 prise administering a therapeutically effective amount of a 
compound comprising at least a portion of an amino acid 
linker-domain from squalene synthase or one that mimics its 
physical and chemical properties, to a subject or patient in 
Regardless of the route of administration, the composi­
tions of the presently-disclosed subject matter typically not 
only include an effective amount of a therapeutic agent, but 
are typically administered in amount effective to achieve the 
desired response. As such, the term "effective amount" is 
used herein to refer to an amount of the therapeutic com­
position sufficient to produce a measurable biological 
response. Actual dosage levels of active ingredients in a 25 
therapeutic composition of the presently-disclosed subject 
matter can be varied so as to administer an amount of the 
active compound(s) that is effective to achieve the desired 
therapeutic response for a particular subject and/or applica­
tion. Of course, the effective amount in any particular case 
will depend upon a variety of factors including the activity 
of the therapeutic composition, formulation, the route of 
administration, combination with other drugs or treatments, 
severity of the condition being treated, and the physical 
condition and prior medical history of the subject being 
treated. Preferably, a minimal dose is administered, and the 
dose is escalated in the absence of dose-limiting toxicity to 
a minimally effective amount. Determination and adjust­
ment of a therapeutically effective dose, as well as evalua­
tion of when and how to make such adjustments, are known 
to those of ordinary skill in the art. 
For additional guidance regarding formulation and dose, 
see U.S. Pat. Nos. 5,326,902; 5,234,933; PCT International 
Publication No. WO 93/25521; Berkow et al., (1997) The 
Merck Manual of Medical Information, Home ed. Merck 
Research Laboratories, Whitehouse Station, New Jersey; 
Goodman et al., (1996) Goodman & Gilman's the Pharma­
cological Basis of Therapeutics, 9th ed. McGraw-Hill 
Health Professions Division, New York; Ebadi, (1998) CRC 
Desk Reference of Clinical Pharmacology. CRC Press, Boca 
Raton, Fla.; Katzung, (2001) Basic & Clinical Pharmacol­
ogy, 8th ed. Lange Medical Books/McGraw-Hill Medical 
Pub. Division, New York; Remington et al., (1975) Rem­
ington's Pharmaceutical Sciences, 15th ed. Mack Pub. Co., 
Easton, Pa.; and Speight et al., (1997) Avery's Drug Treat­
ment: A Guide to the Properties, Choice, Therapeutic Use 
and Economic Value of Drugs in Disease Management, 4th 
ed. Adis International, Auckland/Philadelphia; Duch et al., 
(1998) Toxicol. Lett. 100-101:255-263. 
need of treatment, therefrom. 
Still further provided, in some embodiments, are methods 
for treating or controlling cholesterol metabolism in humans 
by administering a therapeutically effective amount of a 
compound comprising at least a portion of an amino acid 
linker-domain from squalene synthase, to a patient in need 
30 of treatment, therefrom. In some embodiments, a method for 
treating or controlling cholesterol metabolism in humans 
comprises administering to a subject in need thereof an 
effective amount of a compound comprising a polypeptide 
having a sequence of SEQ ID NOS: 1-12 or a polypeptide 
35 which mimics its physical and chemical properties and 
function. 
It will be appreciated that the function of the linker­
domain includes being able to complement an erg9 mutation 
in yeast. Further function includes restoring, in part, 
40 squalene synthases activity in erg9 mutant yeast. Accord­
ingly, a compound consisting essentially of a least a portion 
of an amino acid linker-domain from squalene, in accor­
dance with some embodiments of the presently-disclosed 
subject matter will be the compound having the aforemen-
45 tioned linker-domain and any other portion or modification 
that does not materially affect the function of the compound. 
As used herein, the terms "treatment" or "treating" relate 
to any treatment of a condition of interest ( e.g. controlling 
cholesterol metabolism), including but not limited to pro-
50 phylactic treatment and therapeutic treatment. As such, the 
terms "treatment" or "treating" include, but are not limited 
to: preventing a condition of interest or the development of 
a condition of interest; inhibiting the progression of a 
condition of interest; arresting or preventing the further 
55 development of a condition of interest; reducing the severity 
of a condition of interest; ameliorating or relieving symp­
toms associated with a condition of interest; and causing a 
regression of a condition of interest or one or more of the 
symptoms associated with a condition of interest. 
As used herein, the term "subject" includes human, ani-
mal and plant subjects. Thus, veterinary therapeutic uses are 
provided in accordance with the presently-disclosed subject 
matter. As such, the presently-disclosed subject matter pro­
vides for the treatment of mammals such as humans, as well 
Yet further provided, in some embodiments, are methods 60 
for treating infections including fungal and non-fungal 
infections, e.g. parasitic infections. Examples of parasitic 
infections treated include trypanosomatid infections such as 
those caused by trypanosoma cruzi (Tc) and Leishmania 
donovani (Ld). Tc and Ld have similar squalene synthase 
linker-domains (TcSS and LdSS, respectively) to that for S. 
cerevisiae (ScSS) as shown in the table below: 
65 as those mammals of importance due to being endangered, 
such as Siberian tigers; of economic importance, such as 
animals raised on farms for consumption by humans; and/or 
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animals of social importance to humans, such as animals 
kept as pets or in zoos. Examples of such animals include but 
are not limited to: carnivores such as cats and dogs; swine, 
including pigs, hogs, and wild boars; ruminants and/or 
ungulates such as cattle, oxen, sheep, giraffes, deer, goats, 
bison, and camels; and horses. Also provided is the treat­
ment of birds, including the treatment of those kinds ofbirds 
that are endangered and/or kept in zoos, as well as fowl, and 
more particularly domesticated fowl, i.e., poultry, such as 
turkeys, chickens, ducks, geese, guinea fowl, and the like, as 10 
they are also of economic importance to humans. Thus, also 
provided is the treatment of livestock, including, but not 
limited to, domesticated swine, ruminants, ungulates, horses 
(including race horses), poultry, and the like. 
The practice of the presently-disclosed subject matter can 15 
employ, unless otherwise indicated, conventional techniques 
of cell biology, cell culture, molecular biology, transgenic 
biology, microbiology, recombinant DNA, and immunology, 
which are within the skill of the art. Such techniques are 
explained fully in the literature. See e.g., Molecular Cloning 20 
A Laboratory Manual (1989), 2nd Ed., ed. by Sambrook, 
Fritsch and Maniatis, eds., Cold Spring Harbor Laboratory 
Press, Chapters 16 and 17; U.S. Pat. No. 4,683,195; DNA 
Cloning, Volumes I and II, Glover, ed., 1985; Oligonucle­
otide Synthesis, M. J. Gait, ed., 1984; Nucleic Acid Hybrid- 25 
ization, D. Hames & S. J. Higgins, eds., 1984; Transcription 
and Translation, B. D. Hames & S. J. Higgins, eds., 1984; 
Culture Of Animal Cells, R. I. Freshney, Alan R. Liss, Inc., 
1987; Immobilized Cells And Enzymes, IRL Press, 1986; 
Perbal (1984 ), A Practical Guide To Molecular Cloning; See 30 
Methods In Enzymology (Academic Press, Inc., N.Y.); Gene 
Transfer Vectors For Mammalian Cells, J. H. Miller and M. 
P. Calos, eds., Cold Spring Harbor Laboratory, 1987; Meth­
ods In Enzymology, Vols. 154 and 155, Wu et al., eds.,
Academic Press Inc., N.Y.; Immunochemical Methods In 35 
Cell And Molecular Biology (Mayer and Walker, eds.,
Academic Press, London, 1987; Handbook Of Experimental
Immunology, Volumes I-IV, D. M. Weir and C. C. Black­
well, eds., 1986.
40 
EXPERIMENTS AND EXAMPLES 
The details of one or more embodiments of the presently­
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 45 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem­
plary embodiments, is provided primarily for clearness of 50 
understanding and no unnecessary limitations are to be 
understood therefrom. In case of conflict, the specification of 
this document, including definitions, will control. 
The following results of experiments and examples pro­
vide evidence of efficacy and generation of the aforemen- 55 
tioned compounds and therapeutic treatments. These experi­
ments and examples are intended to be non-limiting, and 
illustrate only certain embodiments of the present invention. 
Furthermore, the examples and experiments may include 
compilations of data that are representative of data gathered 60 
at various times during the course of development and 
experimentation related to the presently-disclosed subject 
matter. 
Complementing the erg9 knockout mutation in yeast 
requires more than active squalene synthase enzyme activity 65 
and squalene accumulation. The following discussion 
describes the process used to develop a complementing 
14 
compound to restore squalene synthase actively in erg9 
knockout mutation yeast and thereby lead to novel com­
pounds, e.g. proteins/peptides. 
Various squalene synthases were cloned into the yeast 
expression vector, Yep352-ADH1, including those from S. 
cerevisiae (YSS), B. braunii (BSS), N. benthamiana (TSS), 
A. thaliana (ASS), and R. norvegicus (RSS), as well as a
C-terminal truncated form ofYSS in which 24 amino acids
comprising the ER membrane-spanning region were elimi­
nated (YSStr). These constructs were transformed into the
yeast line CALI7-1, which has been selected for high level
FPP biosynthesis (10) and has an erg9 knockout mutation. It
is unable to synthesize sterols de nova and is dependent on 
exogenous ergosterol for growth. To test if introducing the
various squalene synthases could restore ergosterol proto­
trophy to CALI7-1 yeast line, colonies testing positive for
the respective SS transgene by PCR screens were grown in
selection media containing ergosterol and serial dilutions
were spotted on plates not containing exogenous ergosterol
(FIG. 1). To evaluate the encoded enzymes for catalytic
activity, extracts prepared from the CALI7-1 yeast lines
were assayed for squalene synthase enzyme activity. Con­
structs were also expressed in TN-7 yeast line and cultures
were grown in liquid media with ergosterol and subse­
quently analyzed for squalene accumulation. Squalene lev­
els were determined in TN-7 because in this yeast line, there
is no possibility of squalene feeding into the ergosterol
biosynthetic pathway. This allows for accurate comparisons
of squalene production by the various SS enzymes.
Interestingly, only the full-length YSS gene and a car­
boxy-terminal truncated form (deletion of the terminal 24 
amino acids) could restore ergosterol prototrophy to the 
Cali7-1 yeast line. Further, significant squalene accumula­
tion and SS enzyme activity was observed in all squalene 
synthase constructs tested, providing evidence that the 
enzyme was properly expressed in an active form in all cases 
(FIG. 1). This provides evidence that all SS enzymes tested 
properly expressed in vivo, but only YSS could complement 
the erg9 deficient CALI7-1 yeast line. 
The terminal membrane-spanning domain of squalene 
synthase is not necessary for functional enzyme nor comple­
mentation of the erg9 mutant. 
To corroborate and extend the earlier observations of 
Kirbii et al (7) that a non-catalytic, carboxy-terminal domain 
was important for complementation, reciprocal molecular 
swaps of the terminal 100 or so amino acids of various plant 
and algae SS enzymes were created with that corresponding 
to the 91 carboxy-terminal amino acids from S. cerevisiae 
SS and tested each for its ability to complement the erg9 
mutation in yeast line CALI7-1 (FIG. 2). As expected, all the 
constructs that contained the carboxy-terminus of S. cerevi­
siae SS were able to complement the erg9 knockout muta­
tion in Cali7-1, while none of the S. cerevisiae SS enzymes 
that had their carboxy-terminus replaced with that of a plant 
or algae SS displayed ergosterol prototrophy. 
Of equal interest is the observation that constructs con­
taining a deletion of the terminal 24 amino acids of the yeast 
SS (YSStr, FIG. 1) or appending this modified terminal 
domain to the algal SS (BSS-YSStr, FIG. 2) did not alter the 
ability of these gene constructs to complement the erg9 
deletion. On the basis of hydropathy plots of this region of 
the SS enzymes (3 ), this terminal region has been referred to 
as a membrane-spanning domain and by inference the 
domain mediating tethering of the SS enzyme activity to the 
ER membrane system in eukaryotic cells (3). Regardless of 
these inferences, the YSStr and BSS-YSStr constructs 
shown in FIGS. 1 and 2 encode for functionally soluble SS 
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enzyme activity ( enzyme activity found in 20,000 g super­
natants of E. coli expressing this genes) and these constructs 
complemented the erg9 mutation in yeast equally well as the 
full-length gene constructs. Hence, the carboxy-terminal 24 
amino acids of the yeast SS are not necessary for the 
complementation phenotype, but some other element(s) 
within the proximal 67 amino acids of the carboxy-terminus 
appears to be both necessary and sufficient for complemen­
tation. 
Computational screens for possible carboxy terminal 10 
domains responsible for the complementation phenotype. 
Because squalene synthase genes from S. cerevisiae (this 
disclosure), S. pombe (3), and Y. lipolytica (8) have been 
demonstrated to complement the erg9 knockout in yeast, but 
squalene synthases from plant, algae and animals carmot, 15 
and because the results in FIGS. 1 and 2 pointed to a 
proximal carboxy terminal region of 67 amino acids being 
responsible for the specificity of this complementation, 
amino acid sequence comparisons of this region between 
relevant squalene synthases were performed. No over-arch- 20 
ing sequence similarities were observed when comparing the 
sequences across this region from algae, plants, animals and 
fungi, although there were greater similarities within the first 
16 
mutants were created in which either the first half (13 
residues) or the second half of the 26 amino acid domain was 
swapped from the A. thaliana SS into the S. cerevisiae 
backbone (FIG. 5, mutants a and b). Swapping out the first 
13 amino acids of the S. cerevisiae SS (FIG. 5, mutant a) had 
no effect on the ability of the subsequent construct to 
complement the erg9 mutation, but swapping the second half 
resulted in a complete loss of the complementation pheno-
type (FIG. 5, mutant b ). Swapping out the first 13 amino 
acids of A. thaliana SS with those in S. cerevisiae also had 
no effect on the ability of this construct to complement the 
erg9 mutant (FIG. 5, mutant f). However, exchanging the 
second half of these residues with those of the yeast squalene 
synthase enabled the construct to restore partial growth to 
the erg9 mutant (FIG. 5, mutant g). Thus, it appeared that the 
residues in the second half of the 26-amino acid domain 
were largely responsible for complementation phenotype 
and this stretch of amino acids was evaluated further. 
Because the KIEQ (SEQ ID NO: 35) and FLKLNIQ 
(SEQ ID NO: 36) stretches of amino acids seem particularly 
conserved amongst the fungal squalene synthases, various 
combinations of these peptide domains were exchanged 
between the ASS and YSS constructs (FIG. 5, mutants c-e 
and h-j). When the "FLKLNIQ" (SEQ ID NO: 36) stretch of 
YSS was replaced with the corresponding domain of ASS 
(FIG. 5, mutant d), complementation growth was not 
affected, and likewise the reciprocal swap in ASS (FIG. 5, 
mutant i) did not restore complementation. However, when 
the "KIEQ" (SEQ ID NO: 35) stretch ofYSS was replaced 
26 amino acids of this region (FIG. 3, bottom portion "B"). 
This degree of similarity became much more apparent when 25 
the alignments of only the fungal squalene synthase were 
compared (FIG. 3, top portion "A"). Within this short 
segment of amino acids, 8 residues are absolutely conserved 
and the degree of amino acid similarity across the entire 26 
amino acids reaches upwards of 45%. 
To functionally evaluate the contribution of this domain to 
the complementation phenotype, reciprocal constructs 
where these 26 amino acids ofYSS were exchanged with the 
corresponding amino acids regions within the BSS and ASS 
were generated. These constructs were transformed into the 35 
erg9 knockout yeast line, and 3 independent colonies from 
each transformation were screened for their ability to grow 
30 with the corresponding domain of ASS (FIG. 5, mutant c), 
growth of the yeast was significantly impaired, suggesting 
that complementation had been affected. The reciprocal 
swap in ASS (FIG. 5, mutant h) did not restore growth of the 
erg9 mutant. Two additional mutants in which the entire 
domains spanning from "FLKLNIQ" (SEQ ID NO: 36) to 
"KIEQ" (SEQ ID NO: 35) were exchanged (FIG. 5, mutant 
e and j) were also evaluated for their ability to complement 
the erg9 mutation. Consistent with our expectations from the 
other mutants, substituting the yeast amino acids of this 
domain with those from the Arabidopsis squalene synthase 
resulted in a complete lose in the ability of this construct to 
complete the erg9 mutation. However, unexpectedly, sub­
stitution of this domain in the Arabidopsis squalene synthase 
gene with that of the yeast squalene synthase only restored 
a very modest level of growth to mutant yeast in the 
complementation tests. All constructs tested in FIG. 5, when 
expressed in yeast, accumulated higher levels of squalene 
and had SS enzyme activity in excess of yeast expressing 
YSS. 
The membrane spanning, carboxy-terminal sequence is 
responsible for localizing squalene synthase to a common 
membrane system. 
One possible explanation for the uniqueness of the car­
boxy-terminal domains would be that the plant carboxy 
termini would target the squalene synthase enzyme to a 
different intracellular compartment than the yeast carboxy 
terminus. To evaluate this possibility, DNA coding for 
different fluorescent tags were appended to the 5' end of the 
yeast, plant or chimera squalene synthase gene and these 
in the absence of ergosterol (FIG. 4). When the carboxy­
terminal 26 amino acid sequence from S. cerevisae was 
substituted into the algal (BSS-YSS-BSS), complementation 40 
was readily apparent. When the carboxy-terminal 26 amino 
acid sequence from S. cerevisae was substituted into the 
Arabidopsis backbone (ASS-YSS-ASS), complementation 
was restored but the growth rate was noticeably affected. 
Further analysis revealed that squalene accumulation in this 45 
yeast line was only about 5% that of the wild type YSS. 
Further, squalene synthase enzyme activity in this yeast line 
was only 7 .6% the level as the YSS-expressing yeast line. 
This provides evidence that the ASS-YSS-ASS was com­
promised in its squalene synthase enzyme activity, but was 50 
still able to complement the erg9 knockout. The reciprocal 
substitutions of inserting the algal or plant amino acid 
sequences into the corresponding site of the S. cerevisiae SS 
resulted in a loss of its ability to complement the erg9 
knockout mutations. The loss of this complementation capa- 55 
bility was not due to a loss in the catalytic activity of the 
yeast SS. When these lines were grown in the presence of 
ergosterol, greater levels of squalene accumulated in these 
cultures relative to those lines transformed with the wild 
type YSS construct or other erg9 complementing constructs 
and SS enzyme activity could be readily measured in yeast 
lysates. 
60 were co-expressed in yeast. The subsequent transformants 
were then subjected to confocal microscopy to visualize the 
intracellular distribution of each protein. If the yeast 
squalene synthase carboxy terminus were to direct proteins 
to a local different from the plant carboxy terminus, then 
Mapping the specific amino acids contributing to the 
complementation phenotype. 
To further assess the contribution of individual amino 
acids within this key stretch of 26 amino acids, fine mapping 
substitution series constructs were generated (FIG. 5). First, 
65 superimposition of the fluorescent images would not be 
expected to overlap and distinct red and green colors would 
be visible. Instead, co-localization should result in over-
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lapping images and color blending (green over-lapping with 
red) would yield a yellow image. FIG. 6 represents, in gray 
scale, rather than color (red/green), that the latter indeed 
occurs, providing strong evidence that the significance of the 
26 amino acid linker domain is not to provide a distinct 
cellular localization signal. 
Over-expression of the 26 amino acid linker domain 
serves to inhibit fungal growth. 
18 
10 
If the fungal 26 amino acid sequence was providing for 
specific and unique interactions between squalene synthase 
and some other factor(s), thus providing for prototrophic 
production of endogenous sterols, then over-expression of 
this peptide fragment might be expected to disrupt normal 
stern! metabolism and hence disrupt fungal growth. To test 
this possibility, a gene coding for the 92 carboxy terminal 15 
residues of the yeast squalene synthase was inserted into a 
galactose inducible expression vector and the recombinant 
vector introduced into a wild type yeast (BY4741) (FIG. 7). 
When grown on glucose, expression of the 92 carboxy­
terminal squalene synthase gene was suppressed and the 20 
transformed yeast grew normally. However, when the same 
transformants were grown on galactose, growth was 
severely arrested. If a plant complementary carboxy-termi­
nal gene was substituted for the yeast, no adverse effects 
were noted. When the 26 amino acid linker domain was 25 
distinctly different between kingdoms. FIG. 8 provides a 
phylogenetic assessment of this domain between the king­
doms of plants, animals and fungi and shows distinct clus­
tering of these domains within squalene synthase genes to 
clades representing only organisms reflecting each of the 
kingdoms. Hence, one would expect that disruption of the 26 
amino acid linker domain within mammalian cells to also 
disrupt cholesterol metabolism, much like we have observed 
for fungi. 
Materials and Methods 
The following disclosure provides background to the 
parameters and the experimental conditions used to generate 
the results discussed above. 
Cloning the Various Squalene Synthases 
Squalene synthases from S. cerevisiae (YSS), B. braunii 
(BSS), R. norvegicus (RSS), N. benthamiana (TSS), and A. 
thaliana (ASS) were cloned from original cell or tissue 
sources. First, total RNA was isolated from the respective 
species using the RNeasy Plant mini kit (Qiagen) or Trizol 
(Invitrogen, for R. norvegicus and S. cerevisiae) according 
to the manufacturer's recommendations, and first strand 
cDNA was synthesized using the SMARTer PCR cDNA 
synthesis kit (Clontech). The first strand cDNA was used as deleted from the yeast gene construct, growth also was not 
impaired. When the deleted region was replaced with the 
correspond domain from a plant (ASS-YSS) or algae (BSS­
Y SS), growth also was unaffected. However, if the yeast 26 
amino acid linker domain was substitute for the correspond­
ing region of the plant (Y SS-ASS) or algal (YSS-BSS) gene, 
then growth was abolished under conditions of induction of 
gene expression (plus galactose). 
The 26 amino acid linker domain is unique to each 
kingdom, and hence represents a target for kingdom specific 
control of stern! metabolism. 
Attention to the 26 amino acid linker domain came about 
because of its unique conservation within fungal squalene 
gene primer 




Xbal Rev trune 
Xhol Rev trune 
N otl Rev trune 
BSS EeoRI For 
HindIII Rev 
Not! Rev 
RSS EeoRI For 
BamHI For trune 
Not! Rev 
Xhol Rev trune 
TSS EeoRI For 
Xbal Rev 
Not! Rev 
ASS EeoRI For 
Xbal Rev 
Not! Rev 
a template to amplify the various squalene synthase genes 
using the primer sets listed in Table 1 (restriction site in 
bold). Y SS was cloned into the Yep352 vector with the Asel 
30 and XbaI sites, and a 3'-truncated form cloned into Yep352 
and pET28a using the Asel and XbaI or BamHI and XhoI 
sites, respectively. BSS was cloned into Yep352 with the 
EcoRI and HindIII sites. RSS was cloned into YEp352 using 
the EcoRI and Natl sites and a 5'- and 3'-truncated RSS was 
35 cloned into pET28a using the BamHI and XhoI sites. TSS 
was cloned into Yep352 with the EcoRI and Natl sites. ASS 
was cloned into Yep352 with the EcoRI and Natl sites. All 
constructs were verified by automated DNA sequencing. 
TABLE 1 























synthases (FIG. 3). If this were to be a universal feature of 
squalene synthases, then one would expect this correspond- 65 
ing domain in plant and animal squalene synthases to be 
highly conserved within that kingdom of organisms, and 
Creating the BSS-YSS fusion 
A reverse primer was designed to pair with the BSS Eco RI 
For (see Table 1), to amplify the first 352 codons of BSS 
except that a single nucleotide mutation was introduced into 
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the 35rd codon to introduce a HindIII restriction site 
without changing the encoded amino acid (ATCCC 
�GCTTCTCTGCTAATTTGAGG (SEQ ID NO: 57), Hin­
dIII site in bold, mutation underlined). This was cloned into 
the pET28a vector with the corresponding restriction sites, 
giving BSS352-pET28a. Another primer was designed to pair 
with either primer, YSS Natl Rev or YSS Natl Rev trunc, to 
amplify YSS starting from codon 353 (ATCCAAGCT­
TAAATCTAAATTGGCTGTGC (SEQ ID NO: 58), HindIII 
site in bold), and these fragments cloned into BSS352-
pET28a cut with HindIII and Natl to give the BSS-YSS and 
BSS-YSStr constructs. These were cut from the pET28a 
vector using EcoRI and Natl and ligated into the corre­
sponding sites of Yep352. The construct was verified by 
automated DNA sequencing. 
fragment was cloned into the NgoMIV and Natl sites of the 
cut Yep352 vector to give BSS-YSS-BSS. The construct was 
verified by automated DNA sequencing. 
Creating Other Fusion Constructs 
All other fusion constructs were created by employing an 
assembly PCR strategy as described by Niehaus et al. (11 ), 
using the primers listed in Tables 1 and 2. For example, 
YSS-BSS was created by using YSS as a template with the 
primer set, YSS-BSS IR and YSS Asel For, to amplify a 
10 fragment of YSS with a 3' overhang, and using BSS as the 
template with the primer set, YSS-BSS IF and BSS HindIII 
Rev, to amplify a fragment of BSS with a 5' overhang. These 
two fragments were both used as templates in a PCR 
reaction with the primer set, YSS Asel For and BSS HindIII 
Creating the BSS-YSS-BSS Expression Cassette 
15 Rev, to give the YSS-BSS construct, which was cloned into 
the YEp352 vector with the corresponding restriction sites. 
YSS-BSS-YSS was created by using YSS-BSS and YSS as 
templates in the initial PCR reaction, and cloning the fin­
ished construct into YEp352 with the Asel and Xbal sites. 
A primer was designed to pair with primer, BSS EcoRI 
For, to amplify a fragment of the BSS-YSS construct with 
NgoMIV and Natl restriction sites (ATAAAGAATGCGGC­
CGCGAATGCCGGCTTCCATAAACTGTTCGATCTTGG 
(SEQ ID NO: 59), NgoMIV and Natl sites in bold). This was 
cloned into the EcoRI and Natl sites of YEp352, which was 
later cut with NgoMIV and Natl. Meanwhile a primer was 
designed to pair with primer, BSS Natl Rev, to amplify a 3' 
region of BSS except that two nucleotide mutations were 
introduced to add an NgoMIV restriction site without chang­
ing the encoded amino acids (GCAAAGAATGC�GG 
�CTGGCACGCACAAAAGATGACACC (SEQ ID NO: 
60), NgoMIV site in bold, mutations underlined). This 




















TSS-YSS and YSS-TSS were cloned into YEp352 with the 
EcoRI and Natl, or Asel and Xbal restriction sites, respec­
tively. YSS-ASS and ASS-YSS were cloned into YEp352 
with Asel and Xbal, or EcoRI and Xbal restriction sites, 
25 respectively. All YSS M( a )-M( e) constructs were cloned into 
YEp352 with the Asel and Xbal restriction sites, and all ASS 
M(f)-M(j) constructs were cloned into YEp352 with EcoRI 
and Xbal restriction sites. All constructs were verified by 
automated DNA sequencing. 
TABLE 2 
Chimeric Sgualene Synthase Primer Sequences. 
SEQ 
ID 
direction sequence NO. 
lF CTTACGTGATATCGAAGTCAGATGCAACACCGAGACCAGCGAGGATCCC 61 
lR GCATCTGACTTCGATATCACGTAAGTAATAGTCAAAAATCTCGACACAGCC 62 
lF CTTACGTGATATCAAGACAAAGGTTGACAAGAACGATCCAAATGCCAG 63 
lR CAACCTTTGTCTTGATATCACGTAAGTAATAGTCAAAAATCTCGACAC 64 
lF CCTGCATGCTGAAATCTAAATTGGCTGTGCAAGATCCAAATTTCTTA 65 
lR GCCAATTTAGATTTCAGCATGCAGGAAAAATCATAGAAAGCACCATAG 66 
lF CTTACGTGATATCAAATCCAAGGTTAATAATAATGATCCAAATGCAAC 67 
lR TTAACCTTGGATTTGATATCACGTAAGTAATAGTCAAAAATCTCGACAC 68 
lF GACTITTCTIGTATGCTGAAATCTAAATTGGCTGTGCAAGATCCAAATTICTT 69 
lR GCCAATTTAGATTICAGCATACAAGAAAAGICAAAAAAAGCACCATATACATC 70 
lF CAAAGCTGCCTGCAAGGAAATGTACCAGGATAAATTACCTCCTAACGTGAAGCC 71 
lR CCTGGTACATTTCCTTGCAGGCAGCTTTGATCTTATGCAGGTGTTCCAGAG 72 
lF AAGACAAAGGTTGACAAGAACGATCCAAATGCCAGTAAGACACTAAACCGACTTGAAGCC 73 
lR TCTGCAGAGTTTCTGAACGGCTTCAAGTCGGTTTAGTGTCTTACTGGCATTTGGATCGTT 74 
lF AAATCTAAATTGGCTGTGCAAGATCCAAATTICTTAAAATTGAACATTCAAATCTCCAAG 75 
lR TTCCATAAACTGITCGATCTIGGAGATTTGAATGITCAATITTAAGAAATTIGGATCTIG 76 
lF CTCCGCCGTTCAAAAGTTTATGGAAGAAATGTACCAGGATAAATTACC 77 
lR CCATAAACTTTTGAACGGCGGAGATTTGAATGTTCAATTTTAAG 78 
lF AATGCCAGTAAGACACTAAACCGTATCTCCAAGATCGAACAGTTTATGG 79 
lR GATACGGTTTAGTGTCTTACTGGCATTTGGATCTTGCACAGCCAATTTAG 80 
lF GCCAGTAAGACACTAAACCGTCTTGAAGCCGTTCAGAAGTTTATGGAAGAAATGTACCAG 81 
lR CTTCTGAACGGCTTCAAGACGGTTTAGTGTCTTACTGGCATTTGGATCTTGCACAGCC 82 
lF AAGACAAAGGTTGACAAGAACGATCCAAATGCCAGTAAGTTGAACATTCAAATCTCCAAG 83 
lR CTTACTGGCATTTGGATCGTTCTTGTCAACCTTTGTCTTGATATCACGTAAGTAATAGTC 84 
lF ACACTAAACCGACTTGAAGCCGTTCAGAAACTCTGCAGAGAAATGTACCAGGATAAATTA 85 
lR TCTGCAGAGTTTCTGAACGGCTTCAAGTCGGTTTAGTGTTTTTAAGAAATTTGGATCTTG 86 
lF CTTGAAAAGATCGAACAGCTCTGCAGAGACGCTGGAGTTCTTC 87 
lR CAGAGCTGTTCGATCTTTTCAAGTCGGTTTAGTGTCTTACTGGC 88 
lF AATTICTTAAAATTGAACATTCAACTTGAAGCCGTICAGAAACTCTGCAG 89 
lR AAGTTGAATGTTCAATTTTAAGAAATTTGGATCGTTCTTGTCAACCTTTG 90 
lF TICTTAAAATTGAACATTCAAATCTCCAAGATCGAACAGCTCTGCAGAGACGCTGGAG 91 
lR CTGTTCGATCTTGGAGATTTGAATGTTCAATTTTAAGAAATTTGGATCGTTCTTGTCAAC 92 
lF AAATCTAAATTGGCTGTGCAAGATCCAAATTICTTAAAAACACTAAACCGACTTGAAGCC 93 
lR TITTAAGAAATTIGGATCTTGCACAGCCAATTTAGATTICAGCATGCAGGAAAAATCATA 94 
lF TTGAACATTCAAATCTCCAAGATCGAACAGITTATGGAAGACGCTGGAGTICTICAAAAC 95 
lR TTCCATAAACTGITCGATCTIGGAGATTTGAATGITCAACTTACTGGCATTIGGATCGTT 96 
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The Erg9 Complementation Assay 
The Cali7-1 yeast line, which has an erg9 deletion so that 
it cannot synthesize sterols de nova and requires exogenous 
ergosterol for growth, was used for these purposes (10). The 
various squalene synthase constructs were transformed into 5 
Cali7-1 yeast using the lithium acetate method and plated on 
Yeast Synthetic Drop-out medium (selection media) lacking 
uracil and containing 5 mg/I ergosterol. Three independent 
CALI7-1 transformants of each construct were randomly 
selected and grown in 2 mL Yeast Synthetic Drop-out media 
10 
(Sigma) containing 5 mg/L ergosterol at 28
° C. for three
days (OD600=6.0±0.3 after three days of growth), after 
which the culture was serially diluted with water to optical 
densities (600 nm) equal to 1, 0.2, 0.04, and 0.008, and 5 µL 
of each dilution spotted onto Yeast Synthetic Drop-out 
15 
media plates without any exogenous ergosterol. Plates were 
incubated at 28° C. for 72 hours.
scintillation spectroscopy. The amount of total protein in the 
yeast supernatants was determined by Bradford Dye assays. 
Enzyme activity (pmole/h/µg total protein) is expressed as a 
percent of S. cerevisiae squalene synthase (YSS) enzyme 
activity. n= 3. 
Creation and Expression of Fluorescent Protein Tagged 
Constructs 
An assembly PCR strategy ( described above) was used to 
create constructs in which either efGFP or DsRedl was 
fused to the amino terminus of various squalene synthase 
enzymes connected by a (GSGG)x2 peptide linker 
sequence. Primers used to create these constructs are listed 
in Table 3 (restriction sites, if any, in bold). For example, 
efGFP-YSS was created by using efGFP as a template with 
the primer set, efGFP Asel For and efGFP lr, to amplify the 
efGFP coding sequence with a 3' overhanging linker 
Liquid cultures of each transformant in TN-7 line were 
grown in 10 mL of Yeast Synthetic Drop-out media con­
taining 5 mg/L ergosterol at room temperature for seven 
days. Organic extracts were prepared and analyzed by 
GC-MS for their squalene content. In brief, 1 mL aliquots of 
the culture were combined with 1 mL of acetone, vigorously 
mixed, and incubated at room temperature for 10 min. One 
mL of hexane was added and mixed vigorously for 60 sec. 
The mixture was then centrifuged briefly at 500xg to sepa­
rate the phases, and an aliquot of the organic phase removed 
and 1-2 µL aliquots analyzed by GC-MS with a Varian 
CP-3800 GC coupled to a Varian Saturn 2200 MS/MS 
(Varian Medical Systems) using a Supelco SLB-5 ms fused 
silica capillary column (30 mx0.25 mmx0.25 µM film 
thickness, Supelco ). Initial oven temperature was set at 220° 
C. for 1 min., ramped to 280° C. at 20° C./min., then ramped
to 300° C. at 3° C./min.
The various SS constructs were expressed in Cali-7 yeast 
and grown for 3 days before 1.5 ml of culture was collected 
by centrifugation and stored at -80 C until further analysis. 
Yeast pellets were resuspended in 0.5 ml buffer (50 mM 
NaH2P04, pH 7.8, 300 mM NaCl, 1 mM MgCl2, 1 mM 
PMSF, 1 % glycerol (v/v)) then sonicated 3x for 5 sec with 
a microprobe sonicator at 60% maximum power. The 
samples were cooled on ice for 2 min between sonication 
treatments. The sonicate was centrifuged at 2,000 g for 10 
min at 4° C. and the supernatant used in enzyme assays.
Assays contained 50 mM Mops, pH 7.3, 20 mM MgCl2, 2.5 
mM 2-mercaptoethanol, 10 µM [1-3H]-FPP (-lx105 dpm 
total), 2 mM NADPH, and 5 µL cell lysate in total reaction 
volume of 50 µL. Reactions were incubated at 37° C. for 1
h and then extracted with 100 µIn-hexane and an aliqout 
spotted on silica-TLC plates with a squalene standard. TLC 
was developed with n-hexane and the squalene zone was 
visualized with iodine vapor, scraped and analyzed by 
sequence, and using YSS as the template with the primer set, 
efGFP-YSS if and YSS XbaI Rev, to amplify YSS with a 5' 
overhanging linker sequence. These two fragments were 
20 
both used as templates in a PCR reaction with the primer set, 
efGFP Asel For and YSS XbaI Rev, to give the efGFP-YSS 
construct, which was cloned into YEp352 with the corre­
sponding restriction sites. Similarly, efGFP-BYB was cre­
ated by using efGFP as the template with the primer set, 
25 
efGFP Asel For and efGFP lr, and using BSS-YSS-BSS as
the template with the primer set, efGFP-BSS if and BSS 
XbaI Rev, in the initial PCR reaction and cloning the 
assembled product into YEp352 with the Asel and XbaI 
sites. DsRedl-BSS was created using DsRedl as the tem-
30 plate with the primer set, DsRedl XhoI For and DsRedl lr, 
and using BSS as the template with the primer set, DsRedl­
BSS if and BSS Natl Rev, in the initial PCR reaction and 
cloning the assembled product into pESC-leu with the XhoI 
and Natl sites. DsRedl-BSS was also cloned into the 
35 
YEp352 vector by amplifying the sequence with the primer
set, DsRedl Asel For and BSS XbaI Rev, and cloning into 
the corresponding restriction sites. efGFP-YSStr was cre­
ated by using efGFP-YSS as the template with the primer 
set, efGFP Asel For and YSStr XbaI Rev, and cloning the 
40 
amplified product into the corresponding sites of YEp352. 
All constructs were verified by automated DNA sequencing. 
A CFP-tagged ER-marker (Pho86p) was kindly provided by 
Dr. Peter Nagy (12). 
Various combinations of fluorescent-tagged squalene syn-
45 thases or a CFP-tagged ER marker were transformed into
Cali-7 yeast. Positive transformants were identified by PCR 
screening and grown in Yeast-synthetic Drop-out media 
containing 5 mg/L ergosterol for three days. Cells were 
collected by brief centrifugation at 500xg and applied to 
50 
glass adhesion microscope slides. Confocal laser scanning
micrographs were acquired on an Olympus FVl 000 micro­
scope (Olympus America Inc., Melville, N.Y.). 
TABLE 3 
Fluorescence protein tagged squalene synthase construct primers 
SEQ ID 
gene/construct primer sequence NO 
efGFP Asel For AGGCGCGCCAAAACAATGTCTAAAGGTGAAGAATTATTC 97 
DsRedl Xhol For CCGCTCGAGAAAACAATGGTGCGCTCCTCCAAGAACGTC 98 
DsRedl Asel For AGGCGCGCCAAAACAATGGTGCGCTCCTCCAAGAACGTC 99 
efGFP lR CATACCAGAACCACCACCAGAACCACCTTTGTACAATTCATCCATACCATGG 100 
DsRedl lR CATACCAGAACCACCACCAGAACCACCCAGGAACAGGTGGTGGCGGCCC 101 
efGFP-YSS lF CAAAGGTGGTTCTGGTGGTGGTTCTGGTATGGGAAAGCTATTACAATTGGC 102 
efGFP-BSS lF CAAAGGTGGTTCTGGTGGTGGTTCTGGTATGGGGATGCTTCGCTGGGGAGTGG 103 
DsRedl-BSS lF CCTGGGTGGTTCTGGTGGTGGTTCTGGTATGGGGATGCTTCGCTGGGGAGTGG 104 
US 9,821,037 Bl 
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TABLE 3-continued 
Fluorescence protein tagged sgualene synthase construct primers 
gene/construct primer sequence 
YSS Xbal Rev GCTCTAGATCACGCTCTGTGTAAAGTGTATATA 
YSStr Xbal Rev GCTCTAGATCACTTGTACTCTTCTTCTTGTTGGGTTGG 
BSS Not! Rev ATAAGAATGCGGCCGCTTAGGCGCTGAGTGTGGGTCTAGG 



































Creating C-Terminus Squalene Synthase Constructs 
Constructs to be tested in S. cerevisiae were created using 
the pESC-Leu vector (Agilent) which harbors the Gall/ 
Gall O divergent promoter to allow for galactose induction of 15
gene expression. Primers used to create these constructs are 
listed in Table 4 (restriction sites, if any, in bold). YSS-92 
was created by PCR amplifying a portion of the YSS gene 
corresponding to the 92 C-terminal amino acids using the 
primer sets, YSS-92 EcoRI For and YSS Natl Rev, and 20 
YSS-92 BamHI For and YSS HindIII Rev, and cloning into 
pESC-Leu with the corresponding restriction enzyme sites. 
ASS-66 and YSS-64 were created in the same mamier. 
ASS-YSS and YSS-ASS were created in a similar manner 
using YSS-ASS-YSS or ASS-YSS-ASS as the templates for 25 
PCR, respectively. BSS-YSS and YSS-BSS were created by 
using YSS-BSS-YSS or BSS-YSS-BSS as the template for 
PCR, respectively. BSS-YSS was only cloned into pESC­
Leu with the EcoRI and Natl restriction sites (GallO pro­
motor) due to a native BamHI restriction site in the BSS- 30 
YSS coding sequence. All constructs were verified by 
automated DNA sequencing. 
It will be understood that various details of the presently 
disclosed subject matter can be departed from the scope of 
the subject matter disclosed herein. Furthermore, the fore­
going, description is for purposes of illustration only, and 
not for the purpose of limitation. 
TABLE 4 
Primers for creating C-terminus sgualene synthase constructs 
primer sequence SEQ ID NOS 
YSS-92 EcoRI For GGAATTCAAAACAATGAAATCTAAATTGGCTGTGCAAGATCC 109 
YSS-92 BamHI For CGGGATCCAAAACAATGAAATCTAAATTGGCTGTGCAAGATCC 110 
YSS-64 EcoRI For GGAATTCAAAACAATGTACCAGGATAAATTACCTCC 
YSS-64 BamHI For CGGGATCCAAAACAATGTACCAGGATAAATTACCTCC 
111 
112 
YSS Not! Rev ATAAGAATGCGGCCGCTCACGCTCTGTGTAAAGTGTATATAT 113 
YSS HindIII Rev AACCCAAGCTTTCACGCTCTGTGTAAAGTGTATATAT 114 
ASS-66 EcoRI For GGAATTCAAAACAATGAAGACAAAGGTTGACAAGAACGATCC 115 
ASS-66 BamHI For CGGGATCCAAAACAATGAAGACAAAGGTTGACAAGAACGATCC 116 
ASS Not! Rev ATAAGAATGCGGCCGCTCAGTTTGCTCTGAGATATGCAAAGAC 117 
ASS HindIII Rev AACCCAAGCTTTCAGTTTGCTCTGAGATATGCAAAGAC 118 
BSS-109 EcoRI For GGAATTCAAAACAATGGAAGTCAGATGCAACACCGAGACC 119 
BSS Not! Rev 






Various references have been cited throughout this dis-
55 closure and include ones listed below. All are herein incor-
Saccharomyces cerevisiae Growth Inhibition Assays 
Constructs were transformed into BY4741 yeast via the 
lithium acetate method and plated on Yeast-Synthetic Drop­
out medium plates lacking uracil. Positive transformants 
were verified by PCR screening and grown in 2 mL of 
Yeast-Synthetic Drop-out medium for 4 days 
(OD
600
=9.0±0.1 after 4 days growth). Cultures were serial 
diluted with water to optical densities (600 nm) equal to 0.5, 60 
0.1, 0.02, and 0.004, and 5 µL of each dilution was spotted 
on selection media containing either 2% glucose or 2% 
galactose as the carbon source. Pictures were taken after 4 
days growth at 28° C. 
The following Table 5 provides a cross reference for this 
disclosure. 
65 
porated by reference. 
1. Fegueur M, Richard L, Charles A D, Karst F (1991)
Isolation and primary structure of the ERG9 gene of
Saccharomyces cerevisiae encoding squalene synthetase.
Current Genetics 20(5), 365-72
2. Jennings S M, Tsay Y H, Fisch TM, Robinson G W
(1991) Molecular cloning and characterization of the
yeast gene for squalene synthetase. Proceedings of the
National Academy of Sciences of the United States of
America 88(14), 6038-42
3. Robinson G W, Tsay Y H, Kienzle BK, Smithmonroy C
A, Bishop R W (1993) Conservation between human and
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fungal squalene synthetases-similarities in structure, 
function, and regulation. Mo! Cell Biol 13:2706-2717. 
4. Soltis D A, et al. Expression, purification, and character­
ization of the human squalene synthase: use of yeast and
baculoviral systems. Archives of Biochemistry and Bio­
physics 316(2), 713-23
5. Nakashima T, Inoue T, Oka A, Nishina T, Osumi T, Hata
S, (1995) Cloning, expression, and characterization of
cDNAs encoding Arabidopsis thaliana squalene syn­
thase. Proceedings of the National Academy of Sciences 
10 of the United States of America 92(6), 2328-32
6. Hanley K et al. (1996) Molecular cloning, in vitro
expression and characterization of a plant squalene syn­
thetase cDNA. Plant Molecular Biology 30(6), 1139-1151
7. Kribii R A et al. (1997) Cloning and characterization of
the Arabidopsis thaliana SQSl gene encoding squalene 15 
synthase. Involvement of the C-terminal region of the
enzyme in the charmeling of squalene through the sterol
pathway. European Journal of Biochemistry 249(1),
61-69
<160> NUMBER OF SEQ ID NOS, 161 
<210> SEQ ID NO 1 
<211> LENGTH, 26 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM: Saccharomyces cerevisiae 
<400> SEQUENCE, 1 
26 
8. Merkulov S et al. (2000) Cloning and characterization of
the Yarrowia lipolytica squalene synthase (SQSl) gene
and functional complementation of the Saccharomyces 
cerevisiae erg9 mutation. Yeast 16(3), 197-206 
9. Busquets A et al. (2008) Arabidopsis thaliana contains a
single gene encoding squalene synthase. Plant Molecular
Biology 67(1-2), 25-36
10. Song L S (2003) Detection of farnesyl diphosphate
accumulation in yeast erg9 mutants. Anal Biochem 317:
180-185.
11. Niehaus T D, et al. (2011) Identification of Unique
Mechanisms for Triterpene Biosynthesis in B. braunii.
Proc Natl Acad Sci USA 108(30), 12260-12265.
12. Panavas T, et al. (2005) The role of the p33:p33/p92
interaction domain in RNA replication and intracellular
localization of p33 and p92 proteins of Cucumber necro­
sis tombusvirus. Virology. 338(1):81-95.
Lys Ser Lys Leu Ala Val Gln Asp Pro Asn Phe Leu Lys Leu Asn Ile 
1 5 10 15 
Gln Ile Ser Lys Ile Glu Gln Phe Met Glu 
20 25 
<210> SEQ ID NO 2 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM: Schizosaccharomyces pombe 
<400> SEQUENCE, 2 
His Tyr Lys Asn Thr Pro Lys Asp Pro Asn Phe Leu Lys Ile Ser Ile 
1 5 10 15 
Glu Cys Gly Lys Ile Glu Gln Val Ser Glu 
20 25 
<210> SEQ ID NO 3 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Yarrowia lipolytica 
<400> SEQUENCE, 3 
Tyr Lys Lys Ser Asp Pro Asn Asp Pro Asn Tyr Phe Arg Val Ser Val 
1 5 10 15 
Leu Cys Gly Lys Ile Glu Gln His Ala Ala 
20 25 
<210> SEQ ID NO 4 
<211> LENGTH, 29 
<212> TYPE, PRT 
<213> ORGANISM: Botryococcus braunii 
<400> SEQUENCE, 4 
Glu Val Arg Cys Asn Thr Glu Thr Ser Glu Asp Pro Ser Val Thr Thr 
1 5 10 15 
US 9,821,037 Bl 
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-continued
Thr Leu Glu His Leu His Lys Ile Lys Ala Ala Cys Lys 
20 25 
<210> SEQ ID NO 5 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Chlamydomonas reinhardtii 
<400> SEQUENCE, 5 
Glu Ala Lys Val Asp Pro Thr Asp Pro Ser Leu Pro Leu Thr Arg Gln 
1 5 10 
Arg Ile Ala Glu Ala Arg Lys Ala Cys Ala 
20 25 
<210> SEQ ID NO 6 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Arabidopsis thaliana 
<400> SEQUENCE, 
Lys Thr Lys Val Asp Lys Asn Asp Pro Asn 
1 5 10 
Arg Leu Glu Ala Val Gln Lys Leu Cys Arg 
20 25 
<210> SEQ ID NO 7 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Nicotiana benthamiana 
<400> SEQUENCE, 7 
Lys Ser Lys Val Asn Asn Asn Asp Pro 
1 5 
Arg Leu Glu Val Ile Leu Lys Thr Cys 
20 25 
<210> SEQ ID NO 8 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 8 
Tyr His Arg Ile Pro Asp Ser Asn Pro 
1 5 
Ile Ile Ser Thr Ile Arg Thr Gln Asn 
20 25 
<210> SEQ ID NO 9 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Rattus norvegicus 
<400> SEQUENCE, 9 
Tyr His Arg Val Pro 
1 5 
Leu Ile Ser Asn Ile 
20 
<210> SEQ ID NO 10
<211> LENGTH, 26 
<212> TYPE, PRT 
Asn Ser Asp Pro 











<213> ORGANISM: Saccharomyces cerevisiae 
15 
Ala Ser Lys Thr Leu Asn 
15 
Ala Thr Lys Thr Leu Lys 
15 
Ser Ser Lys Thr Arg Gln 
15 
Ala Ser Lys Ala Lys Gln 
15 
28 
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<400> SEQUENCE, 10
Lys Ser Lys Leu Ala Val Gln Asp Pro 
1 5 
Gln Ile Ser Lys Ile Glu Gln Phe Met 
20 25 
<210> SEQ ID NO 11 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Schizosaccharomyces 
<400> SEQUENCE, 11 
His Tyr Lys Asn Thr Pro Lys Asp Pro 
1 5 
Glu Cys Gly Lys Ile Glu Gln Val Ser 
20 25 
<210> SEQ ID NO 12
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Yarrowia li polytica 
<400> SEQUENCE, 12
Tyr Lys Lys Ser Asp 
1 5 
Leu Cys Gly Lys Ile 
20 
<210> SEQ ID NO 13 
<211> LENGTH, 67 
<212> TYPE, PRT 
Pro Asn Asp Pro 












<213> ORGANISM: Saccharomyces cerevisiae 
<400> SEQUENCE, 13 
-continued
Leu Lys Leu Asn Ile 
15 
Leu Lys Ile Ser Ile 
15 
Phe Arg Val Ser Val 
15 
Lys Ser Lys Leu Ala Val Gln Asp Pro Asn Phe Leu Lys Leu Asn Ile 
1 5 10 15 
Gln Ile Ser Lys Ile Glu Gln Phe Met Glu Glu Met Tyr Gln Asp Lys 
20 25 30 
Leu Pro Pro Asn Val Lys Pro Asn Glu Thr Pro Ile Phe Leu Lys Val 
35 40 45 
Lys Glu Arg Ser Arg Tyr Asp Asp Glu Leu Val Pro Thr Gln Gln Glu 
50 55 60 
Glu Glu Tyr 
65 
<210> SEQ ID NO 14
<211> LENGTH, 67 
<212> TYPE, PRT 
<213> ORGANISM: Schizosaccharomyces pombe 
<400> SEQUENCE, 14
His Tyr Lys Asn Thr Pro Lys Asp Pro Asn Phe Leu Lys Ile Ser Ile 
1 5 10 15 
Glu Cys Gly Lys Ile Glu Gln Val Ser Glu Ser Leu Phe Pro Arg Arg 
20 25 30 
Phe Arg Glu Met Tyr Glu Lys Ala Tyr Val Ser Lys Leu Ser Glu Gln 
35 40 45 
Lys Lys Gly Asn Gly Thr Gln Lys Ala Ile Leu Asn Asp Glu Gln Lys 
50 55 60 
30 
US 9,821,037 Bl 
Glu Leu Tyr 
65 
<210> SEQ ID NO 15
<211> LENGTH, 67 
<212> TYPE, PRT 
31 
<213> ORGANISM, Yarrowia lipolytica 
<400> SEQUENCE, 15
-continued
Tyr Lys Lys Ser Asp Pro Asn Asp Pro Asn Tyr Phe Arg Val Ser Val 
1 5 10 15 
Leu Cys Gly Lys Ile Glu Gln His Ala Ala Leu Ile Lys Arg Gln Arg 
20 25 30 
Gly Pro Pro Ala Lys Thr Ile Ala Gln Leu Glu Gly Glu Arg Lys Glu 
35 40 45 
Met Ala Leu Ser Leu Ile Val Cys Leu Ala Val Ile Phe Ser Met Ser 
50 55 60 
Gly Leu Met 
65 
<210> SEQ ID NO 16 
<211> LENGTH, 70 
<212> TYPE, PRT 
<213> ORGANISM: Botryococcus braunii 
<400> SEQUENCE, 16 
Glu Val Arg Cys Asn Thr Glu Thr Ser Glu Asp Pro Ser Val Thr Thr 
1 5 10 15 
Thr Leu Glu His Leu His Lys Ile Lys Ala Ala Cys Lys Ala Gly Leu 
20 25 30 
Ala Arg Thr Lys Asp Asp Thr Phe Asp Glu Leu Arg Ser Arg Leu Leu 
35 40 45 
Ala Leu Thr Gly Gly Ser Phe Tyr Leu Ala Trp Thr Tyr Asn Phe Leu 
50 55 60 
Asp Leu Arg Gly Pro Gly 
65 70 
<210> SEQ ID NO 17 
<211> LENGTH, 34 
<212> TYPE, PRT 
<213> ORGANISM, Chlamydomonas reinhardtii 
<400> SEQUENCE, 17 
Glu Ala Lys Val Asp Pro Thr Asp Pro Ser Leu Pro Leu Thr Arg Gln 
1 5 10 15 
Arg Ile Ala Glu Ala Arg Lys Ala Cys Ala Ala Lys Leu Thr Glu Val 
20 25 30 
Ser Val 
<210> SEQ ID NO 18 
<211> LENGTH, 65 
<212> TYPE, PRT 
<213> ORGANISM, Arabidopsis thaliana 
<400> SEQUENCE, 18 
Lys Thr Lys Val Asp Lys Asn Asp Pro Asn Ala Ser Lys Thr Leu Asn 
1 5 10 15 
Arg Leu Glu Ala Val Gln Lys Leu Cys Arg Asp Ala Gly Val Leu Gln 
20 25 30 
32 
US 9,821,037 Bl 
33 
-continued
Asn Arg Lys Ser Tyr Val Asn Asp Lys Gly Gln Pro Asn Ser Val Phe 
35 40 45 
Ile Ile Met Val Val Ile Leu Leu Ala Ile Val Phe Ala Tyr Leu Arg 
50 55 60 
Ala 
65 
<210> SEQ ID NO 19 
<211> LENGTH, 66 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana benthamiana 
<400> SEQUENCE, 19 
Lys Ser Lys Val Asn Asn Asn Asp Pro Asn 
1 5 10 
Arg Leu Glu Val Ile Leu Lys Thr Cys Arg 
20 25 
Ala Thr Lys Thr 





Lys Arg Lys Ser Tyr Ile Ile Arg Ser Glu Pro Asn Tyr Ser Pro Val 
35 40 45 
Leu Ile Val Val Ile Phe Ile Ile Leu Ala Ile Ile Leu Ala Gln Leu 
50 55 60 
Ser Gly 
65 
<210> SEQ ID NO 20
<211> LENGTH, 67 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 20
Tyr His Arg Ile Pro Asp Ser Asn Pro Ser Ser Ser Lys Thr Arg Gln 
1 5 10 15 
Ile Ile Ser Thr Ile Arg Thr Gln Asn Leu Pro Asn Cys Gln Leu Ile 
20 25 30 
Ser Arg Ser His Tyr Ser Pro Ile Tyr Leu Ser Phe Val Met Leu Leu 
35 40 45 
Ala Ala Leu Ser Trp Gln Tyr Leu Thr Thr Leu Ser Gln Val Thr Glu 
50 55 60 
Asp Tyr Val 
65 
<210> SEQ ID NO 21
<211> LENGTH, 67 
<212> TYPE, PRT 
<213> ORGANISM: Rattus norvegicus 
<400> SEQUENCE, 21
Tyr His Arg Val Pro Asn Ser Asp Pro Ser Ala Ser Lys Ala Lys Gln 
1 5 10 15 
Leu Ile Ser Asn Ile Arg Thr Gln Ser Leu Pro Asn Cys Gln Leu Ile 
20 25 30 
Ser Arg Ser His Tyr Ser Pro Ile Tyr Leu Ser Phe Ile Met Leu Leu 
35 40 45 
Ala Ala Leu Ser Trp Gln Tyr Leu Ser Thr Leu Ser Gln Val Thr Glu 
50 55 60 
Asp Tyr Val 
65 
34 
US 9,821,037 Bl 
<210> SEQ ID NO 22
<211> LENGTH, 67 
<212> TYPE, PRT 
35 
<213> ORGANISM: Saccharomyces cerevisiae 
<400> SEQUENCE, 22
-continued
Lys Ser Lys Leu Ala Val Gln Asp Pro Asn Phe Leu Lys Leu Asn Ile 
1 5 10 15 
Gln Ile Ser Lys Ile Glu Gln Phe Met Glu Glu Met Tyr Gln Asp 
20 25 30 
Lys 
Leu Pro Pro Asn Val Lys Pro Asn Glu Thr Pro Ile Phe Leu Lys Val 
35 40 45 
Lys Glu Arg Ser Arg Tyr Asp Asp Glu Leu Val Pro Thr Gln Gln Glu 
50 
Glu Glu Tyr 
65 
<210> SEQ ID NO 23 
<211> LENGTH, 67 
<212> TYPE, PRT 
55 
<213> ORGANISM: Schizosaccharomyces pombe 
<400> SEQUENCE, 23 
60 
His Tyr Lys Asn Thr Pro Lys Asp Pro Asn Phe Leu Lys Ile Ser Ile 
1 5 10 15 
Glu Cys Gly Lys Ile Glu Gln Val Ser Glu Ser Leu Phe Pro Arg 
20 25 30 
Arg 
Phe Arg Glu Met Tyr Glu Lys Ala Tyr Val Ser Lys Leu Ser Glu Gln 
35 
Lys Lys Gly 
50 
Glu Leu Tyr 
65 
Asn Gly Thr 
<210> SEQ ID NO 24
<211> LENGTH, 67 
<212> TYPE, PRT 
40 
Gln Lys Ala Ile Leu 
55 
<213> ORGANISM, Yarrowia lipolytica 
<400> SEQUENCE, 24
45 
Asn Asp Glu Gln Lys 
60 
Tyr Lys Lys Ser Asp Pro Asn Asp Pro Asn Tyr Phe Arg Val Ser Val 
1 5 10 15 
Leu Cys Gly Lys Ile Glu Gln His Ala Ala Leu Ile Lys Arg Gln Arg 
20 25 30 
Gly Pro Pro Ala Lys Thr Ile Ala Gln Leu Glu Gly Glu Arg Lys Glu 
35 40 45 
Met Ala Leu Ser Leu Ile Val Cys Leu Ala Val Ile Phe Ser Met Ser 
50 55 60 
Gly Leu Met 
65 
<210> SEQ ID NO 25
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM: Saccharomyces cerevisiae 
<400> SEQUENCE, 25
Lys Thr Lys Val Asp Lys Asn Asp Pro Asn Ala Ser Lys Leu Asn Ile 
1 5 10 15 
36 
37 
Gln Ile Ser Lys Ile Glu Gln Phe Met Glu 
20 25 
<210> SEQ ID NO 26
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Saccharomyces cerevisiae 
<400> SEQUENCE, 26 
Lys Ser Lys Leu Ala Val Gln Asp Pro Asn 
1 5 10 
Arg Leu Glu Ala Val Gln Lys Leu Cys Arg 
20 25 
<210> SEQ ID NO 27 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Saccharomyces cerevisiae 
<400> SEQUENCE, 27 
Lys Ser Lys Leu Ala Val Gln Asp Pro Asn 
1 5 10 
Gln Ile Ser Ala Val Gln Lys Phe Met Glu 
20 25 
<210> SEQ ID NO 28 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Saccharomyces cerevisiae 
<400> SEQUENCE, 28 
Lys Ser Lys Leu Ala Val Gln Asp Pro Asn 
1 5 10 
Arg Ile Ser Lys Ile Glu Gln Phe Met Glu 
20 25 
<210> SEQ ID NO 29 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Saccharomyces cerevisiae 
<400> SEQUENCE, 29 
Lys Ser Lys Leu Ala Val Gln Asp Pro 
1 5 
Arg Leu Glu Ala Val Gln Lys Phe Met 
20 25 
<210> SEQ ID NO 30 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Arabidopsis thaliana 
<400> SEQUENCE, 30 
Lys Ser Lys Leu Ala 
1 5 
Arg Leu Glu Ala Val 
20 
<210> SEQ ID NO 31 
<211> LENGTH, 26 
<212> TYPE, PRT 
Val Gln Asp Pro 
Gln Lys Leu Cys 
25 
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-continued
Phe Leu Lys Thr Leu Asn 
15 
Phe Leu Lys Leu Asn Ile 
15 
Ala Ser Lys Thr Leu Asn 
15 
Ala Ser Lys Thr Leu Asn 
15 
Phe Leu Lys Thr Leu Asn 
15 
39 
<400> SEQUENCE, 31 
Lys Thr Lys Val Asp Lys Asn Asp Pro Asn 
1 5 10 
Gln Ile Ser Lys Ile Glu Gln Phe Met Glu 
20 25 
<210> SEQ ID NO 32 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Arabidopsis thaliana 
<400> SEQUENCE, 32 
Lys Thr Lys Val Asp Lys Asn Asp Pro Asn 
1 5 10 
Arg Leu Glu Lys Ile Glu Gln Leu Cys Arg 
20 25 
<210> SEQ ID NO 33 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Arabidopsis thaliana 
<400> SEQUENCE, 33 
Lys Thr Lys Val Asp Lys Asn Asp Pro Asn 
1 5 10 
Gln Leu Glu Ala Val Gln Lys Leu Cys Arg 
20 25 
<210> SEQ ID NO 34 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Arabidopsis thaliana 
<400> SEQUENCE, 34 
Lys Thr Lys Val Asp Lys Asn Asp Pro Asn 
1 5 10 
Gln Ile Ser Lys Ile Glu Gln Leu Cys Arg 
20 25 
<210> SEQ ID NO 35 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Saccharomyces cerevisiae 
<400> SEQUENCE, 35 
Lys Ile Glu Gln 
1 
<210> SEQ ID NO 36 
<211> LENGTH, 7 
<212> TYPE, PRT 
<213> ORGANISM, Saccharomyces 
<400> SEQUENCE, 36 
Phe Leu Lys Leu Asn 
1 5 
<210> SEQ ID NO 37




<213> ORGANISM, Artificial Sequence 
<220> FE ATURE, 
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-continued
Ala Ser Lys Leu Asn Ile 
15 
Ala Ser Lys Thr Leu Asn 
15 
Phe Leu Lys Leu Asn Ile 
15 
Phe Leu Lys Leu Asn Ile 
15 
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-continued
<223> OTHER INFORMATION, Squalene synthases from S. cerevisiae cloned 
into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding
<222> LOCATION, (2) .. (9)
<400> SEQUENCE, 37 
aggcgcgcca aaacaatggg aaagctatta caatggc 
<210> SEQ ID NO 38 
<211> LENGTH, 37 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Squalene synthases from S. cerevisiae cloned 
into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (9)
<400> SEQUENCE, 38
cgcggatcca aaacaatggg aaagctatta caatggc 
<210> SEQ ID NO 39
<211> LENGTH, 32 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Squalene synthases from S. cerevisiae cloned 
into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding
<222> LOCATION, (3) .. (8)
<400> SEQUENCE, 39
gctctagatc acgctctgtg taaagtgtat at 
<210> SEQ ID NO 40
<211> LENGTH, 35 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Squalene synthases from S. cerevisiae cloned 
into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding
<222> LOCATION, (9) .. (16)
<400> SEQUENCE, 40
ataagaatgc ggccgctcac gctctgtgta aagtg 
<210> SEQ ID NO 41
<211> LENGTH, 26 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Squalene synthases from S. cerevisiae cloned 
into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding
<222> LOCATION, (3) .. (8)
<400> SEQUENCE, 41
gctctagatc acttgtactc ttcttc 
<210> SEQ ID NO 42
<211> LENGTH, 27
<212> TYPE, DNA 











<223> OTHER INFORMATION, Squalene synthases from S. cerevisiae cloned 
into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (4) .. (9) 
<400> SEQUENCE, 42
gggctcgagt cacttgtact cttcttc 
<210> SEQ ID NO 43
<211> LENGTH, 37 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Squalene synthases from S. cerevisiae cloned 
into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (9) .. (16) 
<400> SEQUENCE, 43
ataagaatgc ggccgctcac ttgtactctt cttcttg 
<210> SEQ ID NO 44
<211> LENGTH, 40 
<212> TYPE, DNA 




<223> OTHER INFORMATION, Squalene synthases from B. braunii cloned into
the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (4) .. (9) 
<400> SEQUENCE, 44
ccggaattca aaacaatggg gatgcttcgc tggggagtgg 
<210> SEQ ID NO 45 
<211> LENGTH, 35 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
40 
<223> OTHER INFORMATION, Squalene synthases from B. braunii cloned into
the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (6) .. (11) 
<400> SEQUENCE, 45 
atcccaagct tttaggcgct gagtgtgggt ctagg 
<210> SEQ ID NO 46 
<211> LENGTH, 40 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
35 
<223> OTHER INFORMATION, Squalene synthases from B. braunii cloned into 
the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (9) .. (16) 
<400> SEQUENCE, 46 
ataagaatgc ggccgcttag gcgctgagtg tgggtctagg 
<210> SEQ ID NO 47
<211> LENGTH, 38 




<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Squalene synthases from R. norvegicus cloned 
into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding
<222> LOCATION, (2) .. (7)
<400> SEQUENCE, 47
ggaattcaaa acaatggagt tcgtgaagtg tctaggcc 
<210> SEQ ID NO 48 
<211> LENGTH, 30 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Squalene synthases from R. norvegicus cloned 
into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (9) 
<400> SEQUENCE, 48 
cgcggatcca tggaccggaa ctcgctcagc 
<210> SEQ ID NO 49
<211> LENGTH, 40 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Squalene synthases from R. norvegicus cloned 
into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding
<222> LOCATION, (9) .. (16) 
<400> SEQUENCE, 49 
ataagaatgc ggccgctcag tgttctctct ggacatagtc 
<210> SEQ ID NO 50 
<211> LENGTH, 34 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Squalene synthases from R. norvegicus cloned 
into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (9) 
<400> SEQUENCE, 50 
ccgctcgagt cagctctgcg tcctgatgtt ggag 
<210> SEQ ID NO 51 
<211> LENGTH, 29 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Squalene synthases from N. benthamiana cloned 
into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding
<222> LOCATION, (2) .. (7)
<400> SEQUENCE, 51 
ggaattcatg gggagtttga gggctattc 
<210> SEQ ID NO 52 








<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence
<220> FEATURE, 
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<223> OTHER INFORMATION, Squalene synthases from N. benthamiana clone d 
into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (3) .. (8) 
<400> SEQUENCE, 52 
gctctagact aagatcggtt tccggatagc 
<210> SEQ ID NO 53 
<211> LENGTH, 38 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence
<220> FEATURE, 
<223> OTHER INFORMATION, Squalene synthases from N. benthamiana clone d 
into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (9) .. (16) 
<400> SEQUENCE, 53 
ataagaatgc ggccgcctaa gatcggtttc cggatagc 
<210> SEQ ID NO 54
<211> LENGTH, 39 
<212> TYPE, DNA 




<223> OTHER INFORMATION, Squalene synthases from A. thaliana clone d into 
the Yep352 vector
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (4) .. (9) 
<400> SEQUENCE, 54
ccggaattca aaacaatggg gagcttgggg acgatgctg 
<210> SEQ ID NO 55 
<211> LENGTH, 29 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence
<220> FEATURE, 
39 
<223> OTHER INFORMATION, Squalene synthases from A. thaliana clone d into 
the Yep352 vector
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (2) .. (7) 
<400> SEQUENCE, 55 
gctctagatc agtttgctct gagatatgc 
<210> SEQ ID NO 56 
<211> LENGTH, 41 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence
<220> FEATURE, 
29 
<223> OTHER INFORMATION, Squalene synthases from A. thaliana clone d into 
the Yep352 vector
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (9) .. (16) 
<400> SEQUENCE, 56 
ataagaatgc ggccgctcag tttgctctga gatatgcaaa g 
<210> SEQ ID NO 57 
41 
48 
<211> LENGTH, 27 
<212> TYPE, DNA 
49 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Reverse primer is designed to pair with the 
Squalene synthases B. braunii EcoRI 
<220> FEATURE, 
<221> NAME/KEY, mutation 
<222> LOCATION, ( 6) .. (11) 
<400> SEQUENCE, 57 
atcccaagct tctctgctaa tttgagg 
<210> SEQ ID NO 58 
<211> LENGTH, 29 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer is designed to pair with the Squalene 
synthases S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, misc_binding
<222> LOCATION, (5) .. (10) 
<400> SEQUENCE, 58 
atccaagctt aaatctaaat tggctgtgc 
<210> SEQ ID NO 59 
<211> LENGTH, 50
<212> TYPE, DNA 













B. braunii EcoRI to amplify a fragment of the BSS-YSS 
with NgoMIV and NotI restriction sites 
misc_binding 
(10) .. (17) 
misc_binding 
(22) .. (27) 
<400> SEQUENCE, 59 
ataaagaatg cggccgcgaa tgccggcttc cataaactgt tcgatcttgg 
<210> SEQ ID NO 60 
<211> LENGTH, 39 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
50 
<223> OTHER INFORMATION, Primer is designed to pair with primer squalene 
synthases B. braunii Not I Rev 
<220> FEATURE, 
<221> NAME/KEY, mutation 
<222> LOCATION, (10) .. (15) 
<400> SEQUENCE, 60 
gcaaagaatg ccggcctggc acgcacaaaa gatgacacc 
<210> SEQ ID NO 61 
<211> LENGTH, 49 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of S. cerevisiae and B. braunii 
<220> FEATURE, 
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (49)
<400> SEQUENCE, 61 
39 
50 
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cttacgtgat atcgaagtca gatgcaacac cgagaccagc gaggatccc 
<210> SEQ ID NO 62 
<211> LENGTH, 51 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of S. cerevisiae and B. braunii 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (51) 
<400> SEQUENCE, 62 
gcatctgact tcgatatcac gtaagtaata gtcaaaaatc tcgacacagc c 
<210> SEQ ID NO 63 
<211> LENGTH, 48 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of S. cerevisiae and A. thaliana 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (48) 
<400> SEQUENCE, 63 
cttacgtgat atcaagacaa aggttgacaa gaacgatcca aatgccag 
<210> SEQ ID NO 64
<211> LENGTH, 48
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of S. cerevisiae and A. thaliana 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (48) 
<400> SEQUENCE, 64
caacctttgt cttgatatca cgtaagtaat agtcaaaaat ctcgacac 
<210> SEQ ID NO 65 
<211> LENGTH, 47 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of A. thaliana and S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (47) 
<400> SEQUENCE, 65 
cctgcatgct gaaatctaaa ttggctgtgc aagatccaaa tttctta 
<210> SEQ ID NO 66 
<211> LENGTH, 48 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of A. thaliana and S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
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<400> SEQUENCE, 66 
gccaatttag atttcagcat gcaggaaaaa tcatagaaag caccatag 
<210> SEQ ID NO 67 
<211> LENGTH, 48 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of S. cerevisiae and N. benthamiana 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (48) 
<400> SEQUENCE, 67 
cttacgtgat atcaaatcca aggttaataa taatgatcca aatgcaac 
<210> SEQ ID NO 68 
<211> LENGTH, 49 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of S. cerevisiae and N. benthamiana 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (49) 
<400> SEQUENCE, 68 
ttaaccttgg atttgatatc acgtaagtaa tagtcaaaaa tctcgacac 
<210> SEQ ID NO 69 
<211> LENGTH, 53 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of N. benthamiana and S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (53) 
<400> SEQUENCE, 69 
gacttttctt gtatgctgaa atctaaattg gctgtgcaag atccaaattt ctt 
<210> SEQ ID NO 70 
<211> LENGTH, 53 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of N. benthamiana and S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (53) 
<400> SEQUENCE, 70 
gccaatttag atttcagcat acaagaaaag tcaaaaaaag caccatatac ate 
<210> SEQ ID NO 71 
<211> LENGTH, 54 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of S. cerevisiae, B. braunii and S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
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<400> SEQUENCE, 71 
caaagctgcc tgcaaggaaa tgtaccagga taaattacct cctaacgtga agcc 
<210> SEQ ID NO 72 
<211> LENG TH, 51 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of S. cerevisiae, B. braunii and S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (51) 
<400> SEQUENCE, 72 
cctggtacat ttccttgcag gcagctttga tcttatgcag gtgttccaga g 
<210> SEQ ID NO 73 
<211> LENG TH, 60 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of S. cerevisiae, A. thaliana and S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (60) 
<400> SEQUENCE, 73 
54 
51 
aagacaaagg ttgacaagaa cgatccaaat gccagtaaga cactaaaccg acttgaagcc 60 
<210> SEQ ID NO 74 
<211> LENG TH, 60 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of S. cerevisiae, A. thaliana and S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (60) 
<400> SEQUENCE, 74 
tctgcagagt ttctgaacgg cttcaagtcg gtttagtgtc ttactggcat ttggatcgtt 60 
<210> SEQ ID NO 75 
<211> LENG TH, 60 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of A. thaliana, S. cerevisiae and A. thaliana 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (60) 
<400> SEQUENCE, 75 
aaatctaaat tggctgtgca agatccaaat ttcttaaaat tgaacattca aatctccaag 60 
<210> SEQ ID NO 76
<211> LENG TH, 60
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Construction of chimeric squalene synthase 
primer sequence of A. thaliana, S. cerevisiae and A. thaliana 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
56 
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<222> LOCATION, (1) .. (60) 
<400> SEQUENCE, 76 
ttccataaac tgttcgatct tggagatttg aatgttcaat tttaagaaat ttggatcttg 60 
<210> SEQ ID NO 77 
<211> LENGTH, 48 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (48) 
<400> SEQUENCE, 77 
ctccgccgtt caaaagttta tggaagaaat gtaccaggat aaattacc 
<210> SEQ ID NO 78 
<211> LENGTH, 44 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (44) 
<400> SEQUENCE, 78 
ccataaactt ttgaacggcg gagatttgaa tgttcaattt taag 
<210> SEQ ID NO 79 
<211> LENGTH, 49 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (49) 
<400> SEQUENCE, 79 
aatgccagta agacactaaa ccgtatctcc aagatcgaac agtttatgg 
<210> SEQ ID NO 80 
<211> LENGTH, 50 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (50) 
<400> SEQUENCE, 80 
gatacggttt agtgtcttac tggcatttgg atcttgcaca gccaatttag 
<210> SEQ ID NO 81 
<211> LENGTH, 60 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase 








<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (60) 
<400> SEQUENCE, 81 
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gccagtaaga cactaaaccg tcttgaagcc gttcagaagt ttatggaaga aatgtaccag 60 
<210> SEQ ID NO 82 
<211> LENGTH, 58 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (58) 
<400> SEQUENCE, 82 
cttctgaacg gcttcaagac ggtttagtgt cttactggca tttggatctt gcacagcc 58 
<210> SEQ ID NO 83 
<211> LENGTH, 60 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (60) 
<400> SEQUENCE, 83 
aagacaaagg ttgacaagaa cgatccaaat gccagtaagt tgaacattca aatctccaag 60 
<210> SEQ ID NO 84 
<211> LENGTH, 60 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (60) 
<400> SEQUENCE, 84 
cttactggca tttggatcgt tcttgtcaac ctttgtcttg atatcacgta agtaatagtc 60 
<210> SEQ ID NO 85 
<211> LENGTH, 60 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (60) 
<400> SEQUENCE, 85 
acactaaacc gacttgaagc cgttcagaaa ctctgcagag aaatgtacca ggataaatta 60 
<210> SEQ ID NO 86
<211> LENGTH, 60
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase 




<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (60) 
<400> SEQUENCE, 86 
US 9,821,037 Bl 
-continued
tctgcagagt ttctgaacgg cttcaagtcg gtttagtgtt tttaagaaat ttggatcttg 60 
<210> SEQ ID NO 87 
<211> LENGTH, 43 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Constructs of A. thaliana squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (43) 
<400> SEQUENCE, 87 
cttgaaaaga tcgaacagct ctgcagagac gctggagttc ttc 
<210> SEQ ID NO 88 
<211> LENGTH, 44 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Constructs of A. thaliana squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (44) 
<400> SEQUENCE, 88 
cagagctgtt cgatcttttc aagtcggttt agtgtcttac tggc 
<210> SEQ ID NO 89 
<211> LENGTH, 50 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Constructs of A. thaliana squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (50) 
<400> SEQUENCE, 89 
aatttcttaa aattgaacat tcaacttgaa gccgttcaga aactctgcag 
<210> SEQ ID NO 90 
<211> LENGTH, 50 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Constructs of A. thaliana squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (50) 
<400> SEQUENCE, 90 
aagttgaatg ttcaatttta agaaatttgg atcgttcttg tcaacctttg 
<210> SEQ ID NO 91 
<211> LENGTH, 58 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 







cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (58) 
<400> SEQUENCE, 91 
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ttcttaaaat tgaacattca aatctccaag atcgaacagc tctgcagaga cgctggag 58 
<210> SEQ ID NO 92 
<211> LENG TH, 60 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Constructs of A. thaliana squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (60) 
<400> SEQUENCE, 92 
ctgttcgatc ttggagattt gaatgttcaa ttttaagaaa tttggatcgt tcttgtcaac 60 
<210> SEQ ID NO 93 
<211> LENG TH, 60 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Constructs of A. thaliana squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (60) 
<400> SEQUENCE, 93 
aaatctaaat tggctgtgca agatccaaat ttcttaaaaa cactaaaccg acttgaagcc 60 
<210> SEQ ID NO 94 
<211> LENG TH, 60 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Constructs of A. thaliana squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (60) 
<400> SEQUENCE, 94 
ttttaagaaa tttggatctt gcacagccaa tttagatttc agcatgcagg aaaaatcata 60 
<210> SEQ ID NO 95 
<211> LENG TH, 60 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Constructs of A. thaliana squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (60) 
<400> SEQUENCE, 95 
ttgaacattc aaatctccaa gatcgaacag tttatggaag acgctggagt tcttcaaaac 60 
<210> SEQ ID NO 96
<211> LENG TH, 60
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
64 
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<223> OTHER INFORMATION, Constructs of A. thaliana squalene synthase 
cloned into the Yep352 vector 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (60) 
<400> SEQUENCE, 96
ttccataaac tgttcgatct tggagatttg aatgttcaac ttactggcat ttggatcgtt 60 
<210> SEQ ID NO 97 
<211> LENGTH, 39 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Fluorescence protein tagged squalene synthase 
construct primer 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (2) .. (9) 
<400> SEQUENCE, 97 
aggcgcgcca aaacaatgtc taaaggtgaa gaattattc 
<210> SEQ ID NO 98 
<211> LENGTH, 39 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Fluorescence protein tagged squalene synthase 
construct primer 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (3) .. (8) 
<400> SEQUENCE, 98 
ccgctcgaga aaacaatggt gcgctcctcc aagaacgtc 
<210> SEQ ID NO 99 
<211> LENGTH, 39 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Fluorescence protein tagged squalene synthase 
construct primer 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (3) .. (9) 
<400> SEQUENCE, 99 
aggcgcgcca aaacaatggt gcgctcctcc aagaacgtc 
<210> SEQ ID NO 100 
<211> LENGTH, 52 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Fluorescence protein tagged squalene synthase 
construct primer 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (52) 
<400> SEQUENCE, 100 
cataccagaa ccaccaccag aaccaccttt gtacaattca tccataccat gg 
<210> SEQ ID NO 101 
<211> LENGTH, 49 
<212> TYPE, DNA 










<223> OTHER INFORMATION, Fluorescence protein tagged squalene synthase 
construct primer 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (49) 
<400> SEQUENCE, 101 
cataccagaa ccaccaccag aaccacccag gaacaggtgg tggcggccc 
<210> SEQ ID NO 102 
<211> LENGTH, 51 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Fluorescence protein tagged squalene synthase 
construct primer 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (51) 
<400> SEQUENCE, 102 
caaaggtggt tctggtggtg gttctggtat gggaaagcta ttacaattgg c 
<210> SEQ ID NO 103 
<211> LENGTH, 53 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Fluorescence protein tagged squalene synthase 
construct primer 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (53) 
<400> SEQUENCE, 103 
caaaggtggt tctggtggtg gttctggtat ggggatgctt cgctggggag tgg 
<210> SEQ ID NO 104 
<211> LENGTH, 53 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Fluorescence protein tagged squalene synthase 
construct primer 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (53) 
<400> SEQUENCE, 104 
cctgggtggt tctggtggtg gttctggtat ggggatgctt cgctggggag tgg 
<210> SEQ ID NO 105 
<211> LENGTH, 33 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Fluorescence protein tagged squalene synthase 
construct primer 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (2) .. (7) 
<400> SEQUENCE, 105 
gctctagatc acgctctgtg taaagtgtat ata 
<210> SEQ ID NO 106 
<211> LENGTH, 38 








<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Fluorescence protein tagged squalene synthase 
construct primer 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (3) .. (8) 
<400> SEQUENCE, 106 
gctctagatc acttgtactc ttcttcttgt tgggttgg 
<210> SEQ ID NO 107
<211> LENG TH, 40 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Fluorescence protein tagged squalene synthase 
construct primer 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, ( 9) .. (16) 
<400> SEQUENCE, 107 
ataagaatgc ggccgcttag gcgctgagtg tgggtctagg 
<210> SEQ ID NO 108 
<211> LENG TH, 32 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Fluorescence protein tagged squalene synthase 
construct primer 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (2) .. (7) 
<400> SEQUENCE, 108 
gctctagatt aggcgctgag tgtgggtcta gg 
<210> SEQ ID NO 109 
<211> LENG TH, 42 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Primer for creating C-terminus squalene 
synthase construct for S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, C_region 
<222> LOCATION, (2) .. (7) 
<400> SEQUENCE, 109 
ggaattcaaa acaatgaaat ctaaattggc tgtgcaagat cc 
<210> SEQ ID NO 110 
<211> LENG TH, 43 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Primer for creating C-terminus squalene 
synthase construct for S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, C_region 
<222> LOCATION, (3) .. (8) 
<400> SEQUENCE, 110 
cgggatccaa aacaatgaaa tctaaattgg ctgtgcaaga tee 
<210> SEQ ID NO 111 
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<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
-continued
<223> OTHER INFORMATION: Primer for creating C-terminus squalene 
synthase construct for S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, C_region 
<222> LOCATION, (2) .. (7) 
<400> SEQUENCE, 111 
ggaattcaaa acaatgtacc aggataaatt acctcc 
<210> SEQ ID NO 112 
<211> LENGTH, 37 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Primer for creating C-terminus squalene 
synthase construct for S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, C_region 
<222> LOCATION, (3) .. (7) 
<400> SEQUENCE, 112 
cgggatccaa aacaatgtac caggataaat tacctcc 
<210> SEQ ID NO 113 
<211> LENGTH, 42 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Primer for creating C-terminus squalene 
synthase construct for S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, C_region 
<222> LOCATION, ( 9) .. (16) 
<400> SEQUENCE, 113 
ataagaatgc ggccgctcac gctctgtgta aagtgtatat at 
<210> SEQ ID NO 114 
<211> LENGTH, 37 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Primer for creating C-terminus squalene 
synthase construct for S. cerevisiae 
<220> FEATURE, 
<221> NAME/KEY, C_region 
<222> LOCATION, (6) .. (11) 
<400> SEQUENCE, 114 
aacccaagct ttcacgctct gtgtaaagtg tatatat 
<210> SEQ ID NO 115 
<211> LENGTH, 42 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Primer for creating C-terminus squalene 
synthase construct for A. thaliana 
<220> FEATURE, 
<221> NAME/KEY, C_region 
<222> LOCATION, (2) .. (7) 
<400> SEQUENCE, 115 
ggaattcaaa acaatgaaga caaaggttga caagaacgat cc 








<212> TYPE, DNA 
73 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION: Primer for creating C-terminus squalene 
synthase construct for A. thaliana 
<220> FEATURE, 
<221> NAME/KEY, C_region 
<222> LOCATION, (3) .. (8) 
<400> SEQUENCE, 116 
cgggatccaa aacaatgaag acaaaggttg acaagaacga tee 
<210> SEQ ID NO 117 
<211> LENGTH, 43
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Primer for creating C-terminus squalene 
synthase construct for A. thaliana 
<220> FEATURE, 
<221> NAME/KEY, C_region 
<222> LOCATION, ( 9) .. (16) 
<400> SEQUENCE, 117 
ataagaatgc ggccgctcag tttgctctga gatatgcaaa gac 
<210> SEQ ID NO 118 
<211> LENGTH, 38
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Primer for creating C-terminus squalene 
synthase construct for A. thaliana 
<220> FEATURE, 
<221> NAME/KEY, C_region 
<222> LOCATION, (6) .. (11) 
<400> SEQUENCE, 118 
aacccaagct ttcagtttgc tctgagatat gcaaagac 
<210> SEQ ID NO 119
<211> LENGTH, 40 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Primer for creating C-terminus squalene 
synthase construct for B. braunii
<220> FEATURE, 
<221> NAME/KEY, C_region 
<222> LOCATION, (2) .. (7) 
<400> SEQUENCE, 119 
ggaattcaaa acaatggaag tcagatgcaa caccgagacc 
<210> SEQ ID NO 120 
<211> LENGTH, 40 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Primer for creating C-terminus squalene 
synthase construct for B. braunii
<220> FEATURE, 
<221> NAME/KEY, C_region 
<222> LOCATION, ( 9) .. (16) 
<400> SEQUENCE, 120 







<210> SEQ ID NO 121 
<211> LENGTH, 35 
<212> TYPE, DNA 
75 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION: Primer for creating C-terminus squalene 
synthase construct for B. braunii 
<220> FEATURE, 
<221> NAM E/KEY, C_region 
<222> LO CATION, (6) .. (11) 
<400> SEQUENCE, 121 
aacccaagct tttaggcgct gagtgtgggt ctagg 
<210> SEQ ID NO 122 
<211> LENGTH, 1335 
<212> TYPE, DNA 
<213> ORGANISM: Saccharomyces cerevisiae 
<400> SEQUENCE, 122 
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg 
aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg 
cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg 
catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc 
atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac 
gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga 
gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat 
caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta 
gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac 
tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc 
aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa 
accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag 
gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa 
ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg 
ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa 
gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat 
gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc 
tgtgtcgaga tttttgacta ttacttacgt gatatcaaat ctaaattggc tgtgcaagat 
ccaaatttct taaaattgaa cattcaaatc tccaagatcg aacagtttat ggaagaaatg 
taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt 
aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag 
ttcaatatgg ttttatctat catcttgtcc gttcttcttg ggttttatta tatatacact 
ttacacagag cgtga 
<210> SEQ ID NO 123 
<211> LENGTH, 1263 
<212> TYPE, DNA 
<213> ORGANISM: Saccharomyces cerevisiae 

























atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg 60 
76 
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aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg 120 
cactgtttcg aactgttgaa cttcacctcc agatcgtttg ctgctgtgat cagagagctg 180 
catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc 240 
atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac 300 
gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga 360 
gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat 420 
caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta 480 
gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac 540 
tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc 600 
aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa 660 
accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag 720 
gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa 780 
ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg 840 
ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa 900 
gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcgat 960 
gtaaagattc gtaagggtac tacctgctgt ttaattttga aatcaaggac tttgcgtggc 1020 
tgtgtcgaga tttttgacta ttacttacgt gatatcaaat ctaaattggc tgtgcaagat 1080 
ccaaatttct taaaattgaa cattcaaatc tccaagatcg aacagtttat ggaagaaatg 1140 
taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt 1200 
aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag 1260 
tga 1263 
<210> SEQ ID NO 124 
<211> LENGTH, 1386 
<212> TYPE, DNA 
<213> ORGANISM, Botryococcus braunii 
<400> SEQUENCE, 124 
atggggatgc ttcgctgggg agtggagtct ttgcagaatc cagatgaatt aatcccggtc 60 
ttgaggatga tttatgctga taagtttgga aagatcaagc caaaggacga agaccggggc 120 
ttctgctatg aaattttaaa ccttgtttca agaagttttg caatcgtcat ccaacagctc 180 
cctgcacagc tgagggaccc agtctgcata ttttaccttg tactacgcgc cctggacaca 240 
gtcgaagatg atatgaaaat tgcagcaacc accaagattc ccttgctgcg tgacttttat 300 
gagaaaattt ctgacaggtc attccgcatg acggccggag atcaaaaaga ctacatcagg 360 
ctgttggatc agtaccccaa agtgacaagc gttttcttga aattgacccc ccgtgaacaa 420 
gagataattg cagacattac aaagcggatg gggaatggaa tggctgactt cgtgcataag 480 
ggtgttcccg acacagtggg ggactacgac ctttactgcc actatgttgc tggggtggtg 540 
ggtctcgggc tttcccagtt gttcgttgcg agtggactac agtcaccctc tttgacccgc 600 
agtgaagacc tttccaatca catgggcctc ttccttcaga agaccaacat catccgcgac 660 
tactttgagg acatcaatga gctgcctgcc ccccggatgt tctggcccag agagatctgg 720 
ggcaagtatg cgaacaacct cgctgagttc aaagacccgg ccaacaaggc ggctgcaatg 780 
tgctgcctca acgagatggt cacagatgca ttgaggcacg cggtgtactg cctgcagtac 840 
atgtccatga ttgaggatcc gcagatcttc aacttctgtg ccatccctca gaccatggcc 900 
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ttcggcaccc tgtctttgtg ttacaacaac tacactatct tcacagggcc caaagcggct 960 
gtgaagctgc gtaggggcac cactgccaag ctgatgtaca cctctaacaa tatgtttgcg 1020 
atgtaccgtc atttcctcaa cttcgcagag aagctggaag tcagatgcaa caccgagacc 1080 
agcgaggatc ccagcgtgac caccactctg gaacacctgc ataagatcaa agctgcctgc 1140 
aaggctgggc tggcacgcac aaaagatgac acctttgacg aattgaggag caggttgtta 1200 
gcgctgacgg gaggcagctt ctacctcgcc tggacctaca atttcctaga ccttcgaggc 1260 
ccgggagacc tgcccacctt cttatctgta acccaacatt ggtggtctat tctgatcttc 1320 
ctcatttcga ttgccgtctt ctttattccg tcgaggccct cacctagacc cacactcagc 1380 
gcctaa 1386 
<210> SEQ ID NO 125 
<211> LENGTH, 1251 
<212> TYPE, DNA 
<213> ORGANISM, Rattus rattus 
<400> SEQUENCE, 125 
atggagttcg tgaagtgtct aggccacccg gaggagttct acaacctgct gcgattccgc 60 
atgggaggcc ggcggaattt catacccaag atggaccgga actcgctcag caacagcttg 120 
aagacttgct ataagtatct tgatcagacc agtcgcagct tcgccgcggt tatccaggcg 180 
ctggatgggg acatacgtca tgcggtgtgt gtgttttacc tgatcctccg agccatggac 240 
acagtggagg atgacatggc catcagtgtg gagaagaaga tcccactgct gcgaaacttt 300 
cacactttcc tctatgagcc ggagtggcgg ttcaccgaga gcaaggagaa gcaccgagta 360 
gtgctggagg acttccccac gatctccctg gagtttagaa atttggctga gaaatatcaa 420 
acagtgatcg ctgacatctg tcacaggatg ggatgtggga tggcagaatt tctaaacaag 480 
gatgtaacct ccaaacagga ctgggacaag tactgtcact atgttgctgg actggtggga 540 
atcggccttt ctcgcctatt ctctgcctca gagtttgaag atcccatagt tggtgaagac 600 
acagagtgtg ccaattctat gggtctgttt ctgcagaaaa caaatatcat tcgtgattat 660 
ctggaagacc aacaagaagg aagacagttt tggcctcaag aggtatgggg caaatatgtt 720 
aagaagctgg aagactttgt taagccagag aacgtagatg tggccgtgaa gtgcttgaat 780 
gaactcataa ccaacgccct acaacacatc cctgacgtca tcacctacct gtcaaggctc 840 
cggaaccaaa gtgtgtttaa cttctgtgcc attccacagg taatggccat tgctacgctg 900 
gctgcctgtt acaataacca tcaggtattc aagggagtag tgaagattcg gaaggggcaa 960 
gcagttaccc tcatgatgga tgccaccaac atgccagctg tcaaagctat catataccag 1020 
tacatagaag agatttatca ccgggtcccc aactcagacc cgtcagctag caaggccaag 1080 
cagctcatct ccaacatcag gacgcagagc cttcccaatt gccagctcat ctcccgaagc 1140 
cactactccc ccatttacct gtccttcatc atgctcttgg ctgccctgag ctggcagtac 1200 
ttgagcactc tgtcccaggt cacagaagac tatgtccaga gagaacactg a 1251 
<210> SEQ ID NO 126 
<211> LENGTH, 1236 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana tabacum 
<400> SEQUENCE, 126 
atggggagtt tgagggctat tctgaagaat ccagaggatt tatatccatt ggtgaagctg 60 
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aagctagcgg ctcgacacgc ggagaagcag atcccgccgt ctccaaattg gggcttctgt 120 
tactcaatgc ttcataaggt ttctcgtagc tttgctctcg tcattcaaca acttccagtc 180 
gagcttcgtg acgccgtgtg cattttctat ttggttcttc gagcacttga cactgttgag 240 
gatgatacca gcattcccac cgatgttaaa gttcctattc tgatctcttt tcatcagcat 300 
gtttatgatc gcgaatggca tttttcatgt ggtacaaagg agtacaaggt tctcatggac 360 
cagttccatc atgtatcaac tgcttttctg gagcttagga aacattatca gcaggcaatt 420 
gaggatatta ccatgaggat gggtgcagga atggcaaaat tcatatgcaa ggaggtggaa 480 
acaaccgatg attatgacga atattgtcac tatgtagctg ggcttgttgg gctaggattg 540 
tcaaaactgt tccatgcctc tgagaaagaa gatctggctt cagattctct ctccaactcc 600 
atgggtttat ttcttcagaa aacaaacatc attagagatt atttggaaga cataaatgaa 660 
gtacccaagt gccgtatgtt ctggccccgt gaaatatgga gtaaatatgt taacaagctt 720 
gaggaattaa agtacgagga taactcggcc aaagcagtgc aatgtctaaa tgacatggtc 780 
actaatgctt tatcacatgt agaagattgt ttgacttaca tgtctgcttt gcgtgatcct 840 
tccatctttc gattctgtgc tattccacag gtcatggcaa ttgggacatt agctatgtgc 900 
tacgacaaca ttgaagtctt cagaggagtg gtaaaaatga gacgtggtct gactgctaag 960 
gtcattgacc ggaccaggac tattgcagat gtatatggtg ctttttttga cttttcttgt 1020 
atgctgaaat ccaaggttaa taataatgat ccaaatgcaa caaaaactct gaagaggctc 1080 
gaagtgatcc tgaaaacttg cagagattcg ggaaccttga acaaaaggaa atcctacata 1140 
atcaggagcg agcctaatta cagtccagtt ctgattgttg tcattttcat catactggct 1200 
attattctcg cacagctatc cggaaaccga tcttag 1236 
<210> SEQ ID NO 127 
<211> LENGTH, 1233 
<212> TYPE, DNA 
<213> ORGANISM, Arabidopsis thaliana 
<400> SEQUENCE, 127 
atggggagct tggggacgat gctgagatat cccgatgata tatatccgct cctgaagatg 60 
aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc 120 
tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc 180 
gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag 240 
gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac 300 
atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac 360 
caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc 420 
gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa 480 
actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg 540 
tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc 600 
aattcaatgg gtttatttct acagaaaaca aacattatca gagattatct tgaggacatt 660 
aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac 720 
aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa 780 
atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt 840 
gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca 900 
ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact 960 
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gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt 
tcctgcatgc tgaagacaaa ggttgacaag aacgatccaa atgccagtaa gacactaaac 
cgacttgaag ccgttcagaa actctgcaga gacgctggag ttcttcaaaa cagaaaatct 
tatgttaatg acaaaggaca accaaacagt gtctttatta taatggttgt gattctactg 
gccatagtct ttgcatatct cagagcaaac tga 
<210> SEQ ID NO 128 
<211> LENGTH, 1335 
<212> TYPE, DNA 







<223> OTHER INFORMATION, Chimeric squalene synthase gene consisting of
1,104 bp of the Botryococcus braunii squalene synthase encoding 
for the amino terminal 368 amino acids and 228 bp of the yeast 
gene encoding for 76 amino acids of the carboxy terminal domain 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (1335) 
<400> SEQUENCE, 128 
atggggatgc ttcgctgggg agtggagtct ttgcagaatc cagatgaatt aatcccggtc 
ttgaggatga tttatgctga taagtttgga aagatcaagc caaaggacga agaccggggc 
ttctgctatg aaattttaaa ccttgtttca agaagttttg caatcgtcat ccaacagctc 
cctgcacagc tgagggaccc agtctgcata ttttaccttg tactacgcgc cctggacaca 
gtcgaagatg atatgaaaat tgcagcaacc accaagattc ccttgctgcg tgacttttat 
gagaaaattt ctgacaggtc attccgcatg acggccggag atcaaaaaga ctacatcagg 
ctgttggatc agtaccccaa agtgacaagc gttttcttga aattgacccc ccgtgaacaa 
gagataattg cagacattac aaagcggatg gggaatggaa tggctgactt cgtgcataag 
ggtgttcccg acacagtggg ggactacgac ctttactgcc actatgttgc tggggtggtg 
ggtctcgggc tttcccagtt gttcgttgcg agtggactac agtcaccctc tttgacccgc 
agtgaagacc tttccaatca catgggcctc ttccttcaga agaccaacat catccgcgac 
tactttgagg acatcaatga gctgcctgcc ccccggatgt tctggcccag agagatctgg 
ggcaagtatg cgaacaacct cgctgagttc aaagacccgg ccaacaaggc ggctgcaatg 
tgctgcctca acgagatggt cacagatgca ttgaggcacg cggtgtactg cctgcagtac 
atgtccatga ttgaggatcc gcagatcttc aacttctgtg ccatccctca gaccatggcc 
ttcggcaccc tgtctttgtg ttacaacaac tacactatct tcacagggcc caaagcggct 
gtgaagctgc gtaggggcac cactgccaag ctgatgtaca cctctaacaa tatgtttgcg 
atgtaccgtc atttcctcaa cttcgcagag aagcttaaat ctaaattggc tgtgcaagat 
ccaaatttct taaaattgaa cattcaaatc tccaagatcg aacagtttat ggaagaaatg 
taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt 
aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag 
ttcaatatgg ttttatctat catctcgtcc gttcttcttg ggttttatta tatatacact 
ttacacagag cgtga 
<210> SEQ ID NO 129
<211> LENGTH, 1263
<212> TYPE, DNA
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<223> OTHER INFORMATION, Chimeric squalene synthase gene consisting of 
1,104 bp of the Botryococcus braunii squalene synthase, followed 
by 155 bp of the carboxy terminal domain of the yeast squalene 
synthase 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (1263) 
<400> SEQUENCE, 129 
atggggatgc ttcgctgggg agtggagtct ttgcagaatc cagatgaatt aatcccggtc 
ttgaggatga tttatgctga taagtttgga aagatcaagc caaaggacga agaccggggc 
ttctgctatg aaattttaaa ccttgtttca agaagttttg caatcgtcat ccaacagctc 
cctgcacagc tgagggaccc agtctgcata ttttaccttg tactacgcgc cctggacaca 
gtcgaagatg atatgaaaat tgcagcaacc accaagattc ccttgctgcg tgacttttat 
gagaaaattt ctgacaggtc attccgcatg acggccggag atcaaaaaga ctacatcagg 
ctgttggatc agtaccccaa agtgacaagc gttttcttga aattgacccc ccgtgaacaa 
gagataattg cagacattac aaagcggatg gggaatggaa tggctgactt cgtgcataag 
ggtgttcccg acacagtggg ggactacgac ctttactgcc actatgttgc tggggtggtg 
ggtctcgggc tttcccagtt gttcgttgcg agtggactac agtcaccctc tttgacccgc 
agtgaagacc tttccaatca catgggcctc ttccttcaga agaccaacat catccgcgac 
tactttgagg acatcaatga gctgcctgcc ccccggatgt tctggcccag agagatctgg 
ggcaagtatg cgaacaacct cgctgagttc aaagacccgg ccaacaaggc ggctgcaatg 
tgctgcctca acgagatggt cacagatgca ttgaggcacg cggtgtactg cctgcagtac 
atgtccatga ttgaggatcc gcagatcttc aacttctgtg ccatccctca gaccatggcc 
ttcggcaccc tgtctttgtg ttacaacaac tacactatct tcacagggcc caaagcggct 
gtgaagctgc gtaggggcac cactgccaag ctgatgtaca cctctaacaa tatgtttgcg 
atgtaccgtc atttcctcaa cttcgcagag aagcttaaat ctaaattggc tgtgcaagat 
ccaaatttct taaaattgaa cattcaaatc tccaagatcg aacagtttat ggaagaaatg 
taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt 
aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag 
tga 
<210> SEQ ID NO 130 
<211> LENGTH, 1386 
<212> TYPE, DNA 
























<223> OTHER INFORMATION, Chimeric squalene synthase consisting of first 
1,056 bp of the yeast squalene synthase gene coding for the first
352 amino acids, followed by 330 bp coding for the carboxy 
terminal 110 amino acids of the Botryococcus braunii squalene 
synthase 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (1386) 
<400> SEQUENCE, 130 
atgggaaagc tattacaatt ggcattgcat 
aagttttgca gaacaccgct attctccatc 
cactgtttcg aactgttgaa cttgacctcc 
catccagaat tgagaaactg tgttactctc 
ccggtcgaga tgaaggcagc tttgaagctg 60 
tatgatcagt ccacgtctcc atatctcttg 120 
agatcgtttg ctgctgtgat cagagagctg 180 
ttttatttga ttttaagggc tttggatacc 240 
86 
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atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac 
gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga 
gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat 
caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta 
gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac 
tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc 
aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa 
accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag 
gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa 
ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg 
ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa 
gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat 
gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc 
tgtgtcgaga tttttgacta ttacttacgt gatatcgaag tcagatgcaa caccgagacc 
agcgaggatc ccagcgtgac caccactctg gaacacctgc ataagatcaa agctgcctgc 
aaggctgggc tggcacgcac aaaagatgac acctttgacg aattgaggag caggttgtta 
gcgctgacgg gaggcagctt ctacctcgcc tggacctaca atttcctaga ccttcgaggc 
ccgggagacc tgcccacctt cttatctgta acccaacatt ggtggtctat tctgatcttc 
ctcatttcga ttgccgtctt ctttattccg tcgaggccct cacctagacc cacactcagc 
gcctaa 
<210> SEQ ID NO 131 
<211> LENGTH, 1257 
<212> TYPE, DNA 






















<223> OTHER INFORMATION, Chimeric squalene synthase consisting of first 
1,056 bp of the yeast squalene synthase gene coding for the first 
352 amino acids, followed by 201 bp coding for the carboxy 
terminal 67 amino acids of the Arabidopsis thaliana squalene 
synthase 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (1257) 
<400> SEQUENCE, 131 
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg 60 
aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg 120 
cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg 180 
catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc 240 
atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac 300 
gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga 360 
gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat 420 
caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta 480 
gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac 540 
tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc 600 
aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa 660 
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accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag 
gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa 
ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg 
ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa 
gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat 
gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc 
tgtgtcgaga tttttgacta ttacttacgt gatatcaaga caaaggttga caagaacgat 
ccaaatgcca gtaagacact aaaccgactt gaagccgttc agaaactctg cagagacgct 
ggagttcttc aaaacagaaa atcttatgtt aatgacaaag gacaaccaaa cagtgtcttt 
attataatgg ttgtgattct actggccata gtctttgcat atctcagagc aaactga 
<210> SEQ ID NO 132 
<211> LENGTH, 1311 
<212> TYPE, DNA 












<223> OTHER INFORMATION, Chimeric squalene synthase consisting of first 
1,032 bp of the Arabidopsis squalene synthase gene coding for the 
first 344 amino acids, followed by 276 bp coding for the carboxy 
terminal 92 amino acids of the yeast squalene synthase 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (1311) 
<400> SEQUENCE, 132 
atggggagct tggggacgat gctgagatat ccggatgaca tatatccgct cctgaagatg 
aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc 
tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc 
gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag 
gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac 
atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac 
caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc 
gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa 
actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg 
tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc 
aattcaatgg gtttatttct gcagaaaaca aacattatca gagattatct tgaggacatt 
aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac 
aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa 
atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt 
gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca 
ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact 
gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt 
tcctgcatgc tgaaatctaa attggctgtg caagatccaa atttcttaaa attgaacatt 
caaatctcca agatcgaaca gtttatggaa gaaatgtacc aggataaatt acctcctaac 
gtgaagccaa atgaaactcc aattttcttg aaagttaaag aaagatccag atacgatgat 
gaattggttc caacccaaca agaagaagag tacaagttca atatggtttt atctatcatc 
























<210> SEQ ID NO 133 
<211> LENGTH, 1266 
<212> TYPE, DNA 
91 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Chimeric squalene synthase consisting of 1,062 
bp of the yeast squalene synthase gene coding for the first 354 
amino acids, followed by 201 bp coding for the carboxy terminal 67 
amino acids of the tobacco squalene synthase 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (1266) 
<400> SEQUENCE, 133 
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg 
aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg 
cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg 
catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc 
atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac 
gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga 
gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat 
caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta 
gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac 
tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc 
aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa 
accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag 
gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa 
ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg 
ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa 
gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat 
gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc 
tgtgtcgaga tttttgacta ttacttacgt gatatcaaat ccaaggttaa taataatgat 
ccaaatgcaa caaaaactct gaagaggctc gaagtgatcc tgaaaacttg cagagattcg 
ggaaccttga acaaaaggaa atcctacata atcaggagcg agcctaatta cagtccagtt 
ctgattgttg tcattttcat catactggct attattctcg cacagctatc cggaaaccga 
tcttag 
<210> SEQ ID NO 134 
<211> LENGTH, 1305 
<212> TYPE, DNA 
























<223> OTHER INFORMATION, Chimeric squalene synthase consisting of 1,029 
bp of the tobacco squalene synthase gene coding for the first 343 
amino acids, followed by 273 bp coding for the carboxy terminal 91
amino acids of the yeast squalene synthase 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (1305) 
<400> SEQUENCE, 134 
atggggagtt tgagggctat tctgaagaat ccagaggatt tatatccatt ggtgaagctg 60 
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aagctagcgg ctcgacacgc ggagaagcag atcccgccgt ctccaaattg gggcttctgt 
tactcaatgc ttcataaggt ttctcgtagc tttgctctcg tcattcaaca acttccagtc 
gagcttcgtg acgccgtgtg cattttctat ttggttcttc gagcacttga cactgttgag 
gatgatacca gcattcccac cgatgttaaa gttcctattc tgatctcttt tcatcagcat 
gtttatgatc gcgaatggca tttttcatgt ggtacaaagg agtacaaggt tctcatggac 
cagttccatc atgtatcaac tgcttttctg gagcttagga aacattatca gcaggcaatt 
gaggatatta ccatgaggat gggtgcagga atggcaaaat tcatatgcaa ggaggtggaa 
acaaccgatg attatgacga atattgtcac tatgtagctg ggcttgttgg gctaggattg 
tcaaaactgt tccatgcctc tgagaaagaa gatctggctt cagattctct ctccaactcc 
atgggtttat ttcttcagaa aacaaacatc attagagatt atttggaaga cataaatgaa 
gtacccaagt gccgtatgtt ctggccccgt gaaatatgga gtaaatatgt taacaagctt 
gaggaattaa agtacgagga taactcggcc aaagcagtgc aatgtctaaa tgacatggtc 
actaatgctt tatcacatgt agaagattgt ttgacttaca tgtctgcttt gcgtgatcct 
tccatctttc gattctgtgc tattccacag gtcatggcaa ttgggacatt agctatgtgc 
tacgacaaca ttgaagtctt cagaggagtg gtaaaaatga gacgtggtct gactgctaag 
gtcattgacc ggaccaggac tattgcagat gtatatggtg ctttttttga cttttcttgt 
atgctgaaat ctaaattggc tgtgcaagat ccaaatttct taaaattgaa cattcaaatc 
tccaagatcg aacagtttat ggaagaaatg taccaggata aattacctcc taacgtgaag 
ccaaatgaaa ctccaatttt cttgaaagtt aaagaaagat ccagatacga tgatgaattg 
gttccaaccc aacaagaaga agagtacaag ttcaatatgg ttttatctat catcttgtcc 
gttcttcttg ggttttatta tatatacact ttacacagag cgtga 
<210> SEQ ID NO 135 
<211> LENGTH, 1377 
<212> TYPE, DNA 























<223> OTHER INFORMATION, Chimeric squalene synthase consisting of 1,056 
bp of the B. braunii squalene synthase gene coding for the first 
352 amino acids, followed by 84 bp encoding for 28 amino acids of 
a linker domain of the yeast squalene synthase, then 234 bp of 
the B. 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (1377) 
<400> SEQUENCE, 135 
atggggatgc ttcgctgggg agtggagtct ttgcagaatc cagatgaatt aatcccggtc 60 
ttgaggatga tttatgctga taagtttgga aagatcaagc caaaggacga agaccggggc 120 
ttctgctatg aaattttaaa ccttgtttca agaagttttg caatcgtcat ccaacagctc 180 
cctgcacagc tgagggaccc agtctgcata ttttaccttg tactacgcgc cctggacaca 240 
gtcgaagatg atatgaaaat tgcagcaacc accaagattc ccttgctgcg tgacttttat 300 
gagaaaattt ctgacaggtc attccgcatg acggccggag atcaaaaaga ctacatcagg 360 
ctgttggatc agtaccccaa agtgacaagc gttttcttga aattgacccc ccgtgaacaa 420 
gagataattg cagacattac aaagcggatg gggaatggaa tggctgactt cgtgcataag 480 
ggtgttcccg acacagtggg ggactacgac ctttactgcc actatgttgc tggggtggtg 540 
ggtctcgggc tttcccagtt gttcgttgcg agtggactac agtcaccctc tttgacccgc 600 
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agtgaagacc tttccaatca catgggcctc ttccttcaga agaccaacat catccgcgac 
tactttgagg acatcaatga gctgcctgcc ccccggatgt tctggcccag agagatctgg 
ggcaagtatg cgaacaacct cgctgagttc aaagacccgg ccaacaaggc ggctgcaatg 
tgctgcctca acgagatggt cacagatgca ttgaggcacg cggtgtactg cctgcagtac 
atgtccatga ttgaggatcc gcagatcttc aacttctgtg ccatccctca gaccatggcc 
ttcggcaccc tgtctttgtg ttacaacaac tacactatct tcacagggcc caaagcggct 
gtgaagctgc gtaggggcac cactgccaag ctgatgtaca cctctaacaa tatgtttgcg 
atgtaccgtc atttcctcaa cttcgcagag aagcttaaat ctaaattggc tgtgcaagat 
ccaaatttct taaaattgaa cattcaaatc tccaagatcg aacagtttat ggaagccggc 
ctggcacgca caaaagatga cacctttgac gaattgagga gcaggttgtt agcgctgacg 
ggaggcagct tctacctcgc ctggacctac aatttcctag accttcgagg cccgggagac 
ctgcccacct tcttatctgt aacccaacat tggtggtcta ttctgatctt cctcatttcg 
attgccgtct tctttattcc gtcgaggccc tcacctagac ccacactcag cgcctaa 
<210> SEQ ID NO 136 
<211> LENGTH, 1344 
<212> TYPE, DNA 















<223> OTHER INFORMATION, Chimeric squalene synthase consisting of 1,056 
bp of the yeast squalene synthase gene coding for the first 352 
amino acids, followed by 87 bp encoding for 29 amino acids of a 
linker domain of the B. braunii squalene synthase, then 201 bp of 
the yeast 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (1344) 
<400> SEQUENCE, 136 
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg 
aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg 
cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg 
catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc 
atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac 
gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga 
gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat 
caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta 
gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac 
tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc 
aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa 
accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag 
gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa 
ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg 
ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa 
gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat 
gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc 
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agcgaggatc ccagcgtgac caccactctg gaacacctgc ataagatcaa agctgcctgc 
aaggaaatgt accaggataa attacctcct aacgtgaagc caaatgaaac tccaattttc 
ttgaaagtta aagaaagatc cagatacgat gatgaattgg ttccaaccca acaagaagaa 
gagtacaagt tcaatatggt tttatctatc atcttgtccg ttcttcttgg gttttattat 
atatacactt tacacagagc gtga 
<210> SEQ ID NO 137 
<211> LENGTH, 1335 
<212> TYPE, DNA 







<223> OTHER INFORMATION, Chimeric squalene synthase consisting of 1,056 
bp of the yeast squalene synthase gene coding for the first 352 
amino acids, followed by 78 bp encoding for 26 amino acids of a 
linker domain of the Arabidopsis squalene synthase, then 201 bp of 
the yeast 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (1335) 
<400> SEQUENCE, 137 
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg 
aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg 
cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg 
catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc 
atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac 
gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga 
gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat 
caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta 
gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac 
tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc 
aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa 
accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag 
gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa 
ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg 
ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa 
gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat 
gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc 
tgtgtcgaga tttttgacta ttacttacgt gatatcaaga caaaggttga caagaacgat 
ccaaatgcca gtaagacact aaaccgactt gaagccgttc agaaactctg cagagaaatg 
taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt 
aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag 
ttcaatatgg ttttatctat catcttgtcc gttcttcttg ggttttatta tatatacact 
ttacacagag cgtga 
<210> SEQ ID NO 138 
<211> LENGTH, 1233 
<212> TYPE, DNA 
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<223> OTHER INFORMATION, Chimeric squalene synthase consisting of 1,032 
bp of the Arabidopsis squalene synthase gene coding for the first 
344 amino acids, followed by 78 bp encoding for 26 amino acids of 
a linker domain of the yeast squalene synthase, then 120 bp of the 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1) .. (1233) 
<400> SEQUENCE, 138 
atggggagct tggggacgat gctgagatat cccgatgata tatatccgct cctgaagatg 
aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc 
tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc 
gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag 
gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac 
atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac 
caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc 
gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa 
actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg 
tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc 
aattcaatgg gtttatttct acagaaaaca aacattatca gagattatct tgaggacatt 
aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac 
aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa 
atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt 
gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca 
ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact 
gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt 
tcctgcatgc tgaaatctaa attggctgtg caagatccaa atttcttaaa attgaacatt 
caaatctcca agatcgaaca gtttatggaa gacgctggag ttcttcaaaa cagaaaatct 
tatgttaatg acaaaggaca accaaacagt gtctttatta taatggttgt gattctactg 
gccatagtct ttgcatatct cagagcaaac tga 
<210> SEQ ID NO 139 
<211> LENGTH, 1335 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: S. cerevisiae squalene synthase constructs 
cloned into YEp352
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1057) .. (1095) 






















atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg 60 
aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg 120 
cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg 180 
catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc 240 
atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac 300 
gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga 360 
gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat 420 
100 
US 9,821,037 Bl 
101 
-continued
caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta 
gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac 
tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc 
aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa 
accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag 
gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa 
ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg 
ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa 
gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat 
gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc 
tgtgtcgaga tttttgacta ttacttacgt gatatcaaga caaaggttga caagaacgat 
ccaaatgcca gtaagttgaa cattcaaatc tccaagatcg aacagtttat ggaagaaatg 
taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt 
aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag 
ttcaatatgg ttttatctat catcttgtcc gttcttcttg ggttttatta tatatacact 
ttacacagag cgtga 
<210> SEQ ID NO 140 
<211> LENGTH, 1335 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: S. cerevisiae squalene synthase constructs 
cloned into YEp353 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1096) .. (1134) 

















atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg 60 
aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg 120 
cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg 180 
catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc 240 
atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac 300 
gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga 360 
gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat 420 
caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta 480 
gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac 540 
tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc 600 
aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa 660 
accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag 720 
gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa 780 
ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg 840 
ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa 900 
gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat 960 
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gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc 
tgtgtcgaga tttttgacta ttacttacgt gatatcaaat ctaaattggc tgtgcaagat 
ccaaatttct taaaaacact aaaccgactt gaagccgttc agaaactctg cagagaaatg 
taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt 
aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag 
ttcaatatgg ttttatctat catcttgtcc gttcttcttg ggttttatta tatatacact 
ttacacagag cgtga 
<210> SEQ ID NO 141 
<211> LENGTH, 1335 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: S. cerevisiae squalene synthase constructs 
cloned into YEp354 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1114) .. (1125) 
<400> SEQUENCE, 141 
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg 
aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg 
cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg 
catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc 
atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac 
gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga 
gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat 
caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta 
gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac 
tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc 
aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa 
accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag 
gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa 
ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg 
ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa 
gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat 
gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc 
tgtgtcgaga tttttgacta ttacttacgt gatatcaaat ctaaattggc tgtgcaagat 
ccaaatttct taaaattgaa cattcaaatc tccgccgttc aaaagtttat ggaagaaatg 
taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt 
aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag 
ttcaatatgg ttttatctat catcttgtcc gttcttcttg ggttttatta tatatacact 
ttacacagag cgtga 
<210> SEQ ID NO 142 
<211> LENGTH, 1335 
<212> TYPE, DNA 




































<223> OTHER INFORMATION: S. cerevisiae squalene synthase constructs 
cloned into YEp355 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1087) .. (1107) 
<400> SEQUENCE, 142 
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg 
aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg 
cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg 
catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc 
atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac 
gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga 
gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat 
caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta 
gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac 
tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc 
aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa 
accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag 
gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa 
ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg 
ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa 
gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat 
gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc 
tgtgtcgaga tttttgacta ttacttacgt gatatcaaat ctaaattggc tgtgcaagat 
ccaaatgcca gtaagacact aaaccgtatc tccaagatcg aacagtttat ggaagaaatg 
taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt 
aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag 
ttcaatatgg ttttatctat catcttgtcc gttcttcttg ggttttatta tatatacact 
ttacacagag cgtga 
<210> SEQ ID NO 143 
<211> LENGTH, 1335 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence
<220> FEATURE, 
<223> OTHER INFORMATION: S. cerevisiae squalene synthase constructs 
cloned into YEp356 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1087) .. (1125) 
























atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg 60 
aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg 120 
cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg 180 
catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc 240 
atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac 300 
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gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga 
gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat 
caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta 
gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac 
tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc 
aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa 
accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag 
gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa 
ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg 
ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa 
gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat 
gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc 
tgtgtcgaga tttttgacta ttacttacgt gatatcaaat ctaaattggc tgtgcaagat 
ccaaatgcca gtaagacact aaaccgtctt gaagccgttc agaagtttat ggaagaaatg 
taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt 
aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag 
ttcaatatgg ttttatctat catcttgtcc gttcttcttg ggttttatta tatatacact 
ttacacagag cgtga 
<210> SEQ ID NO 144 
<211> LENGTH, 1233 
<212> TYPE, DNA 




















<223> OTHER INFORMATION, A. thaliana squalene synthase constructs cloned
into YEp357 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1033) .. (1071) 
<400> SEQUENCE, 144 
atggggagct tggggacgat gctgagatat cccgatgata tatatccgct cctgaagatg 60 
aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc 120 
tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc 180 
gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag 240 
gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac 300 
atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac 360 
caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc 420 
gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa 480 
actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg 540 
tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc 600 
aattcaatgg gtttatttct acagaaaaca aacattatca gagattatct tgaggacatt 660 
aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac 720 
aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa 780 
atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt 840 
gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca 900 
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ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact 
gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt 
tcctgcatgc tgaaatctaa attggctgtg caagatccaa atttcttaaa aacactaaac 
cgacttgaag ccgttcagaa actctgcaga gacgctggag ttcttcaaaa cagaaaatct 
tatgttaatg acaaaggaca accaaacagt gtctttatta taatggttgt gattctactg 
gccatagtct ttgcatatct cagagcaaac tga 
<210> SEQ ID NO 145 
<211> LENGTH, 1233 
<212> TYPE, DNA 








<223> OTHER INFORMATION, A. thaliana squalene synthase constructs cloned 
into YEp358 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1072) .. (1110) 
<400> SEQUENCE, 145 
atggggagct tggggacgat gctgagatat cccgatgata tatatccgct cctgaagatg 
aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc 
tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc 
gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag 
gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac 
atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac 
caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc 
gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa 
actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg 
tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc 
aattcaatgg gtttatttct acagaaaaca aacattatca gagattatct tgaggacatt 
aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac 
aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa 
atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt 
gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca 
ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact 
gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt 
tcctgcatgc tgaagacaaa ggttgacaag aacgatccaa atgccagtaa gttgaacatt 
caaatctcca agatcgaaca gtttatggaa gacgctggag ttcttcaaaa cagaaaatct 
tatgttaatg acaaaggaca accaaacagt gtctttatta taatggttgt gattctactg 
gccatagtct ttgcatatct cagagcaaac tga 
<210> SEQ ID NO 146 
<211> LENGTH, 1233 
<212> TYPE, DNA 























<223> OTHER INFORMATION, A. thaliana squalene synthase constructs cloned 
into YEp359 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
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<222> LOCATION, (1090) .. (1101)
<400> SEQUENCE, 146
atggggagct tggggacgat gctgagatat cccgatgata tatatccgct cctgaagatg 
aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc 
tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc 
gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag 
gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac 
atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac 
caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc 
gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa 
actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg 
tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc 
aattcaatgg gtttatttct acagaaaaca aacattatca gagattatct tgaggacatt 
aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac 
aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa 
atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt 
gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca 
ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact 
gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt 
tcctgcatgc tgaagacaaa ggttgacaag aacgatccaa atgccagtaa gacactaaac 
cgacttgaaa agatcgaaca gctctgcaga gacgctggag ttcttcaaaa cagaaaatct 
tatgttaatg acaaaggaca accaaacagt gtctttatta taatggttgt gattctactg 
gccatagtct ttgcatatct cagagcaaac tga 
<210> SEQ ID NO 147 
<211> LENGTH, 1233 
<212> TYPE, DNA 























<223> OTHER INFORMATION, A. thaliana squalene synthase constructs cloned 
into YEp360 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1063) .. (1083) 
<400> SEQUENCE, 147 
atggggagct tggggacgat gctgagatat cccgatgata tatatccgct cctgaagatg 60 
aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc 120 
tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc 180 
gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag 240 
gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac 300 
atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac 360 
caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc 420 
gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa 480 
actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg 540 
tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc 600 
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aattcaatgg gtttatttct acagaaaaca aacattatca gagattatct tgaggacatt 
aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac 
aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa 
atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt 
gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca 
ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact 
gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt 
tcctgcatgc tgaagacaaa ggttgacaag aacgatccaa atttcttaaa attgaacatt 
caacttgaag ccgttcagaa actctgcaga gacgctggag ttcttcaaaa cagaaaatct 
tatgttaatg acaaaggaca accaaacagt gtctttatta taatggttgt gattctactg 
gccatagtct ttgcatatct cagagcaaac tga 
<210> SEQ ID NO 148 
<211> LENGTH, 1233 
<212> TYPE, DNA 













<223> OTHER INFORMATION, A. thaliana squalene synthase constructs cloned 
into YEp361 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1063) .. (1101) 
<400> SEQUENCE, 148 
atggggagct tggggacgat gctgagatat cccgatgata tatatccgct cctgaagatg 
aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc 
tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc 
gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag 
gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac 
atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac 
caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc 
gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa 
actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg 
tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc 
aattcaatgg gtttatttct acagaaaaca aacattatca gagattatct tgaggacatt 
aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac 
aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa 
atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt 
gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca 
ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact 
gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt 
tcctgcatgc tgaagacaaa ggttgacaag aacgatccaa atttcttaaa attgaacatt 
caaatctcca agatcgaaca gctctgcaga gacgctggag ttcttcaaaa cagaaaatct 
tatgttaatg acaaaggaca accaaacagt gtctttatta taatggttgt gattctactg 























<210> SEQ ID NO 149 
<211> LENGTH, 282 
<212> TYPE, DNA 
115 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION: C-terminus S. cerevisiae squalene synthase 
construct 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (4) .. (282) 






<210> SEQ ID NO 150 
<211> LENGTH, 198 


















<223> OTHER INFORMATION: C-terminus S. cerevisiae squalene synthase 
construct 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (4) .. (198) 






atgtaccagg ataaattacc tcctaacgtg aagccaaatg aaactccaat tttcttgaaa 60 
gttaaagaaa gatccagata cgatgatgaa ttggttccaa cccaacaaga agaagagtac 120 
aagttcaata tggttttatc tatcatcttg tccgttcttc ttgggtttta ttatatatac 180 
actttacaca gagcgtga 198 
<210> SEQ ID NO 151 
<211> LENGTH, 204 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, C-terminus A. thaliana squalene synthase 
construct 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (4) .. (204) 
<400> SEQUENCE, 151 
atgaagacaa aggttgacaa gaacgatcca aatgccagta agacactaaa ccgacttgaa 60 
gccgttcaga aactctgcag agacgctgga gttcttcaaa acagaaaatc ttatgttaat 120 
gacaaaggac aaccaaacag tgtctttatt ataatggttg tgattctact ggccatagtc 180 
tttgcatatc tcagagcaaa ctga 204 
<210> SEQ ID NO 152 
<211> LENGTH, 204 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: C-terminus S. cerevisiae and A. thaliana 
squalene synthase construct 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (4) .. (204) 
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<400> SEQUENCE, 152 
atgaaatcta aattggctgt gcaagatcca aatttcttaa aattgaacat tcaaatctcc 60 
aagatcgaac agtttatgga agacgctgga gttcttcaaa acagaaaatc ttatgttaat 120 
gacaaaggac aaccaaacag tgtctttatt ataatggttg tgattctact ggccatagtc 180 
tttgcatatc tcagagcaaa ctga 204 
<210> SEQ ID NO 153 
<211> LENGTH, 282 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence
<220> FEATURE, 
<223> OTHER INFORMATION: C-terminus A. thaliana and S. cerevisiae
squalene synthase construct 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (4) .. (282) 
<400> SEQUENCE, 153 
atgaagacaa aggttgacaa gaacgatcca aatgccagta agacactaaa ccgacttgaa 60 
gccgttcaga aactctgcag agaaatgtac caggataaat tacctcctaa cgtgaagcca 120 
aatgaaactc caattttctt gaaagttaaa gaaagatcca gatacgatga tgaattggtt 180 
ccaacccaac aagaagaaga gtacaagttc aatatggttt tatctatcat cttgtccgtt 240 
cttcttgggt tttattatat atacacttta cacagagcgt ga 
<210> SEQ ID NO 154
<211> LENGTH, 291
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence
<220> FEATURE, 
<223> OTHER INFORMATION: C-terminus B. braunii and S. cerevisiae
squalene synthase construct 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (4) .. (291) 
<400> SEQUENCE, 154 
282 
atggaagtca gatgcaacac cgagaccagc gaggatccca gcgtgaccac cactctggaa 60 
cacctgcata agatcaaagc tgcctgcaag gaaatgtacc aggataaatt acctcctaac 120 
gtgaagccaa atgaaactcc aattttcttg aaagttaaag aaagatccag atacgatgat 180 
gaattggttc caacccaaca agaagaagag tacaagttca atatggtttt atctatcatc 240 
ttgtccgttc ttcttgggtt ttattatata tacactttac acagagcgtg a 291 
<210> SEQ ID NO 155 
<211> LENGTH, 324 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence
<220> FEATURE, 
<223> OTHER INFORMATION: C-terminus S. cerevisiae and B. braunii 
squalene synthase construct 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (4) .. (324) 
<400> SEQUENCE, 155 
atgaaatcta aattggctgt gcaagatcca aatttcttaa aattgaacat tcaaatctcc 60 
aagatcgaac agtttatgga agccggcctg gcacgcacaa aagatgacac ctttgacgaa 120 
ttgaggagca ggttgttagc gctgacggga ggcagcttct acctcgcctg gacctacaat 180 
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ttcctagacc ttcgaggccc gggagacctg cccaccttct tatctgtaac ccaacattgg 240 
tggtctattc tgatcttcct catttcgatt gccgtcttct ttattccgtc gaggccctca 300 
cctagaccca cactcagcgc ctaa 324 
<210> SEQ ID NO 156 
<211> LENGTH, 282 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Fusion of Aspergillus squalene synthase - yeast 
squalene synthase 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (4) .. (81) 
<400> SEQUENCE, 156 
atgcacaaga agaacacacc caaggacccc aatttcctaa aaatcagtat cgtctgcggc 60 
aagattgaga aatttatcga ggaaatgtac caggataaat tacctcctaa cgtgaagcca 120 
aatgaaactc caattttctt gaaagttaaa gaaagatcca gatacgatga tgaattggtt 180 
ccaacccaac aagaagaaga gtacaagttc aatatggttt tatctatcat cttgtccgtt 240 
cttcttgggt tttattatat atacacttta cacagagcgt ga 
<210> SEQ ID NO 157 
<211> LENGTH, 2073 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Fluorescence protein tagged S. cerevisiae 
squalene synthase construct 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (715) .. (738) 
<400> SEQUENCE, 157 
atgtctaaag gtgaagaatt attcactggt gttgtcccaa ttttggttga attagatggt 
gatgttaatg gtcacaaatt ttctgtctcc ggtgaaggtg aaggtgatgc tacttacggt 
aaattgacct taaaatttat ttgtactact ggtaaattgc cagttccatg gccaacctta 
gtcactactt tcggttatgg tgttcaatgt tttgcgagat acccagatca tatgaaacaa 
catgactttt tcaagtctgc catgccagaa ggttatgttc aagaaagaac tatttttttc 
aaagatgacg gtaactacaa gaccagagct gaagtcaagt ttgaaggtga taccttagtt 
aatagaatcg aattaaaagg tattgatttt aaagaagatg gtaacatttt aggtcacaaa 
ttggaataca actataactc tcacaatgtt tacatcatgg ctgacaaaca aaagaatggt 
atcaaagtta acttcaaaat tagacacaac attgaagatg gttctgttca attagctgac 
cattatcaac aaaatactcc aattggtgat ggtccagtct tgttaccaga caaccattac 
ttatccactc aatctgcctt atccaaagat ccaaacgaaa agacagacca catggtcttg 
ttagaatttg ttactgctgc tggtattacc catggtatgg atgaattgta caaaggtggt 
tctggtggtg gttctggtat gggaaagcta ttacaattgg cattgcatcc ggtcgagatg 
aaggcagctt tgaagctgaa gttttgcaga acaccgctat tctccatcta tgatcagtcc 
acgtctccat atctcttgca ctgtttcgaa ctgttgaact tgacctccag atcgtttgct 
gctgtgatca gagagctgca tccagaattg agaaactgtg ttactctctt ttatttgatt 
ttaagggctt tggataccat cgaagacgat atgtccatcg aacacgattt gaaaattgac 
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cccgatgtga aggacagagc cgttttgaca gatttcgaat cgattcttat tgaattccac 
aaattgaaac cagaatatca agaagtcatc aaggagatca ccgagaaaat gggtaatggt 
atggccgact acatcttaga tgaaaattac aacttgaatg ggttgcaaac cgtccacgac 
tacgacgtgt actgtcacta cgtagctggt ttggtcggtg atggtttgac ccgtttgatt 
gtcattgcca agtttgccaa cgaatctttg tattctaatg agcaattgta tgaaagcatg 
ggtcttttcc tacaaaaaac caacatcatc agagattaca atgaagattt ggtcgatggt 
agatccttct ggcccaagga aatctggtca caatacgctc ctcagttgaa ggacttcatg 
aaacctgaaa acgaacaact ggggttggac tgtataaacc acctcgtctt aaacgcattg 
agtcatgtta tcgatgtgtt gacttatttg gccggtatcc acgagcaatc cactttccaa 
ttttgtgcca ttccccaagt tatggccatt gcaaccttgg ctttggtatt caacaaccgt 
gaagtgctac atggcaatgt aaagattcgt aagggtacta cctgctattt aattttgaaa 
tcaaggactt tgcgtggctg tgtcgagatt tttgactatt acttacgtga tatcaaatct 
aaattggctg tgcaagatcc aaatttctta aaattgaaca ttcaaatctc caagatcgaa 
cagtttatgg aagaaatgta ccaggataaa ttacctccta acgtgaagcc aaatgaaact 
ccaattttct tgaaagttaa agaaagatcc agatacgatg atgaattggt tccaacccaa 
caagaagaag agtacaagtt caatatggtt ttatctatca tcttgtccgt tcttcttggg 
ttttattata tatacacttt acacagagcg tga 
<210> SEQ ID NO 158 
<211> LENGTH, 2088 
<212> TYPE, DNA 



















<223> OTHER INFORMATION, Fluorescence protein tagged B. braunii squalene 
synthase construct
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (679) .. (702) 
<400> SEQUENCE, 158 
atggtgcgct cctccaagaa cgtcatcaag gagttcatgc gcttcaaggt gcgcatggag 60 
ggcaccgtga acggccacga gttcgagatc gagggcgagg gcgagggccg cccctacgag 120 
ggccacaaca ccgtgaagct gaaggtgacc aagggcggcc ccctgccctt cgcctgggac 180 
atcctgtccc cccagttcca gtacggctcc aaggtgtacg tgaagcaccc cgccgacatc 240 
cccgactaca agaagctgtc cttccccgag ggcttcaagt gggagcgcgt gatgaacttc 300 
gaggacggcg gcgtggtgac cgtgacccaa gactcctccc tgcaggacgg ctgcttcatc 360 
tacaaggtga agttcatcgg cgtgaacttc ccctccgacg gccccgtaat gcagaagaag 420 
accatgggct gggaggcctc caccgagcgc ctgtaccccc gcgacggcgt gctgaagggc 480 
gagatccaca aggccctgaa gctgaaggac ggcggccact acctggtgga gttcaagtcc 540 
atctacatgg ccaagaagcc cgtgcagctg cccggctact actacgtgga ctccaagctg 600 
gacatcacct cccacaacga ggactacacc atcgtggagc agtacgagcg caccgagggc 660 
cgccaccacc tgttcctggg tggttctggt ggtggttctg gtatggggat gcttcgctgg 720 
ggagtggagt ctttgcagaa tccagatgaa ttaatcccgg tcttgaggat gatttatgct 780 
gataagtttg gaaagatcaa gccaaaggac gaagaccggg gcttctgcta tgaaatttta 840 
aaccttgttt caagaagttt tgcaatcgtc atccaacagc tccctgcaca gctgagggac 900 
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ccagtctgca tattttacct tgtactacgc gccctggaca cagtcgaaga tgatatgaaa 
attgcagcaa ccaccaagat tcccttgctg cgtgactttt atgagaaaat ttctgacagg 
tcattccgca tgacggccgg agatcaaaaa gactacatca ggctgttgga tcagtacccc 
aaagtgacaa gcgttttctt gaaattgacc ccccgtgaac aagagataat tgcagacatt 
acaaagcgga tggggaatgg aatggctgac ttcgtgcata agggtgttcc cgacacagtg 
ggggactacg acctttactg ccactatgtt gctggggtgg tgggtctcgg gctttcccag 
ttgttcgttg cgagtggact acagtcaccc tctttgaccc gcagtgaaga cctttccaat 
cacatgggcc tcttccttca gaagaccaac atcatccgcg actactttga ggacatcaat 
gagctgcctg ccccccggat gttctggccc agagagatct ggggcaagta tgcgaacaac 
ctcgctgagt tcaaagaccc ggccaacaag gcggctgcaa tgtgctgcct caacgagatg 
gtcacagatg cattgaggca cgcggtgtac tgcctgcagt acatgtccat gattgaggat 
ccgcagatct tcaacttctg tgccatccct cagaccatgg ccttcggcac cctgtctttg 
tgttacaaca actacactat cttcacaggg cccaaagcgg ctgtgaagct gcgtaggggc 
accactgcca agctgatgta cacctctaac aatatgtttg cgatgtaccg tcatttcctc 
aacttcgcag agaagctgga agtcagatgc aacaccgaga ccagcgagga tcccagcgtg 
accaccactc tggaacacct gcataagatc aaagctgcct gcaaggctgg gctggcacgc 
acaaaagatg acacctttga cgaattgagg agcaggttgt tagcgctgac gggaggcagc 
ttctacctcg cctggaccta caatttccta gaccttcgag gcccgggaga cctgcccacc 
ttcttatctg taacccaaca ttggtggtct attctgatct tcctcatttc gattgccgtc 
ttctttattc cgtcgaggcc ctcacctaga cccacactca gcgcctaa 
<210> SEQ ID NO 159 
<211> LENGTH, 2115 
<212> TYPE, DNA 






















<223> O THER INFORMATION, Fluorescence protein tagged B. braunii squalene 
synthase construct 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (715) .. (738) 
<220> FEATURE, 
<221> NAME/KEY, misc_binding 
<222> LOCATION, (1795) .. (1872) 
<400> SEQUENCE, 159 
atgtctaaag gtgaagaatt attcactggt gttgtcccaa ttttggttga attagatggt 60 
gatgttaatg gtcacaaatt ttctgtctcc ggtgaaggtg aaggtgatgc tacttacggt 120 
aaattgacct taaaatttat ttgtactact ggtaaattgc cagttccatg gccaacctta 180 
gtcactactt tcggttatgg tgttcaatgt tttgcgagat acccagatca tatgaaacaa 240 
catgactttt tcaagtctgc catgccagaa ggttatgttc aagaaagaac tatttttttc 300 
aaagatgacg gtaactacaa gaccagagct gaagtcaagt ttgaaggtga taccttagtt 360 
aatagaatcg aattaaaagg tattgatttt aaagaagatg gtaacatttt aggtcacaaa 420 
ttggaataca actataactc tcacaatgtt tacatcatgg ctgacaaaca aaagaatggt 480 
atcaaagtta acttcaaaat tagacacaac attgaagatg gttctgttca attagctgac 540 
cattatcaac aaaatactcc aattggtgat ggtccagtct tgttaccaga caaccattac 600 
ttatccactc aatctgcctt atccaaagat ccaaacgaaa agacagacca catggtcttg 660 
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ttagaatttg ttactgctgc tggtattacc catggtatgg atgaattgta caaaggtggt 
tctggtggtg gttctggtat ggggatgctt cgctggggag tggagtcttt gcagaatcca 
gatgaattaa tcccggtctt gaggatgatt tatgctgata agtttggaaa gatcaagcca 
aaggacgaag accggggctt ctgctatgaa attttaaacc ttgtttcaag aagttttgca 
atcgtcatcc aacagctccc tgcacagctg agggacccag tctgcatatt ttaccttgta 
ctacgcgccc tggacacagt cgaagatgat atgaaaattg cagcaaccac caagattccc 
ttgctgcgtg acttttatga gaaaatttct gacaggtcat tccgcatgac ggccggagat 
caaaaagact acatcaggct gttggatcag taccccaaag tgacaagcgt tttcttgaaa 
ttgacccccc gtgaacaaga gataattgca gacattacaa agcggatggg gaatggaatg 
gctgacttcg tgcataaggg tgttcccgac acagtggggg actacgacct ttactgccac 
tatgttgctg gggtggtggg tctcgggctt tcccagttgt tcgttgcgag tggactacag 
tcaccctctt tgacccgcag tgaagacctt tccaatcaca tgggcctctt ccttcagaag 
accaacatca tccgcgacta ctttgaggac atcaatgagc tgcctgcccc ccggatgttc 
tggcccagag agatctgggg caagtatgcg aacaacctcg ctgagttcaa agacccggcc 
aacaaggcgg ctgcaatgtg ctgcctcaac gagatggtca cagatgcatt gaggcacgcg 
gtgtactgcc tgcagtacat gtccatgatt gaggatccgc agatcttcaa cttctgtgcc 
atccctcaga ccatggcctt cggcaccctg tctttgtgtt acaacaacta cactatcttc 
acagggccca aagcggctgt gaagctgcgt aggggcacca ctgccaagct gatgtacacc 
tctaacaata tgtttgcgat gtaccgtcat ttcctcaact tcgcagagaa gcttaaatct 
aaattggctg tgcaagatcc aaatttctta aaattgaaca ttcaaatctc caagatcgaa 
cagtttatgg aagccggcct ggcacgcaca aaagatgaca cctttgacga attgaggagc 
aggttgttag cgctgacggg aggcagcttc tacctcgcct ggacctacaa tttcctagac 
cttcgaggcc cgggagacct gcccaccttc ttatctgtaa cccaacattg gtggtctatt 
ctgatcttcc tcatttcgat tgccgtcttc tttattccgt cgaggccctc acctagaccc 
acactcagcg cctaa 
<210> SEQ ID NO 160 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM: Trypanosoma cruzi 
<400> SEQUENCE, 160 
Ala Ala Arg Met Asn Ala Gln Asp Ala Cys Tyr Asp Arg Ile Glu His 
1 5 10 15 
Leu Val Asn Asp Ala Ile Arg Ala Met Glu 
20 25 
<210> SEQ ID NO 161 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM: Leishmania donovani 
<400> SEQUENCE, 161 
Gln Lys Lys Leu Asp Val Gln Asp Ala Ser Ser Thr Ser Ile Ala Asn 
1 5 10 15 
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The invention claimed is: 
1. A compound consisting of an amino acid sequence
selected from the group consisting of SEQ ID NOs: 1-12 and 
161, wherein the compound inhibits fungal growth. 
2. The compound of claim 1, wherein the amino acid 5
sequence is SEQ ID NO: 1. 
3. The compound of claim 1, wherein the amino acid
sequence is selected from the group consisting of SEQ ID 
NOs: 2-12. 
* * * * * 
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